Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, ” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ~~Age.~~ ☒Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 3, 2017,~~August 5, 2022, the registrant had ~~15,413,610~~3,343,070 shares of common stock outstanding.

	September 30, 2017			December 31, 2016			June 30, 2022			December 31, 2021
	(Unaudited)						(Unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	10,412,968		$	9,007,071		$	13,450,949		$	9,144,710
Accounts receivable, net								365,643			295,193
Prepaid expenses		334,728			267,711			307,919			923,746
Inventory, net								268,334			185,534
Other current assets	—				7,997			11,551			11,551
Total current assets		10,747,696			9,282,779			14,404,396			10,560,734
Other assets		11,551			11,551
Operating lease right-of-use asset								—			12,428
Total assets	$	10,759,247		$	9,294,330		$	14,404,396		$	10,573,162

Liabilities and stockholders' equity
Current Liabilities:
Accounts payable and accrued expenses	$	1,720,816		$	478,223		$	824,481		$	874,028
Accrued compensation		927,843			933,450			528,665			519,317
Operating lease liability								—			12,428
Total current liabilities		2,648,659			1,411,673			1,353,146			1,405,773
Warrant liability		6,050,901			4,095,019
Long-term Liabilities:
Note payable								5,000,000			5,000,000
Accrued interest payable								860,240			612,295
Total long-term liabilities								5,860,240			5,612,295
Total liabilities		8,699,560			5,506,692			7,213,386			7,018,068

Commitments and contingencies (Note 3)

Stockholders' equity:
Common stock, $0.0001 par value; authorized shares - 50,000,000; issued and outstanding shares - 15,413,610 and 12,350,360 at September 30, 2017 and December 31, 2016, respectively		1,541			1,235
Common stock, $0.0001 par value; authorized shares — 50,000,000 at June 30, 2022 and December 31, 2021; issued and outstanding shares — 3,343,070 and 2,721,373 at June 30, 2022 and December 31, 2021, respectively								334			272
Additional paid-in capital		72,788,358			62,595,546			119,020,734			110,977,835
Accumulated deficit		(70,730,212	)		(58,809,143	)		(111,830,058	)		(107,423,013	)
Total stockholders' equity		2,059,687			3,787,638			7,191,010			3,555,094
Total liabilities and stockholders' equity	$	10,759,247		$	9,294,330		$	14,404,396		$	10,573,162

Three Months Ended
September 30,

Nine Months Ended
September 30,

2017

2016

2017

2016

Operating expenses:

Research and development

$
2,717,698

$
1,339,343

$
5,505,953

$
5,449,568

General and administrative

984,047

830,092

3,065,595

2,770,500

Total operating expenses

3,701,745

2,169,435

8,571,548

8,220,068

Loss from operations

(3,701,745
)

(2,169,435
)

(8,571,548
)

(8,220,068
)
Other income (expense):

   Interest income (expense), net

2,822

(123,209
)

5,452

(268,483
)
   Financing costs related to warrant liability

—

(533,692
)

—

(533,692
)
   Change in fair value of warrant liability

(1,544,138
)

(198,945
)

(3,354,973
)

(198,945
)
Total other expense, net

(1,541,316
)

(855,846
)

(3,349,521
)

(1,001,120
)
Net loss

$
(5,243,061
)

$
(3,025,281
)

$
(11,921,069
)

$
(9,221,188
)

Net loss per share of common stock, basic

$
(0.34
)

$
(0.29
)

$
(0.81
)

$
(1.11
)

Net loss per share of common stock, diluted

$
(0.34
)

$
(0.29
)

$
(0.89
)

$
(1.11
)
Weighted-average shares used to compute basic
net loss per share

15,351,295

10,614,692

14,740,977

8,341,750

Weighted-average shares used to compute diluted net loss per share

15,351,295

10,614,692

14,766,853

8,341,750

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021

Net product sales	$	461,795		$	236,635		$	880,175		$	327,056
Operating expenses:
Cost of goods sold		67,774			68,253			90,535			133,004
Research and development		191,478			195,229			233,194			473,054
Selling, general and administrative		2,315,175			2,142,149			4,720,251			4,480,443
Total operating expenses		2,574,427			2,405,631			5,043,980			5,086,501
Loss from operations		(2,112,632	)		(2,168,996	)		(4,163,805	)		(4,759,445	)
Other income (expense):
Forgiveness of paycheck protection loan and accrued interest		—			—			—			105,130
Interest income		3,910			3,011			4,705			6,174
Interest expense		(124,658	)		(124,658	)		(247,945	)		(247,997	)
Total other income (expense)		(120,748	)		(121,647	)		(243,240	)		(136,693	)
Net loss	$	(2,233,380	)	$	(2,290,643	)	$	(4,407,045	)	$	(4,896,138	)

Net loss per share of common stock, basic and diluted	$	(0.71	)	$	(0.85	)	$	(1.50	)	$	(1.85	)

Weighted-average shares used to compute basic and diluted net loss per share		3,156,925			2,698,833			2,944,183			2,647,669

					Additional					Total
	Common Stock				Paid-In		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Equity
Balance at January 1, 2022		2,721,373	$	272	$	110,977,835	$	(107,423,013	)	$	3,555,094
Stock-based compensation expense	—		—			381,061	—				381,061
Issuance of common stock, net of costs of $3,548		21,783	2			171,519	—				171,521
Net loss	—		—		—			(2,173,665	)		(2,173,665	)
Balance at March 31, 2022		2,743,156		274		111,530,415		(109,596,678	)		1,934,011
Stock-based compensation expense	—		—			366,924	—				366,924
Issuance of common stock net of costs of $145,445		599,914		60		7,123,395	—				7,123,455
Net loss	—		—		—			(2,233,380	)		(2,233,380	)
Balance at June 30, 2022		3,343,070	$	334	$	119,020,734	$	(111,830,058	)	$	7,191,010


					Additional					Total
	Common Stock				Paid-In		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Equity (Deficit)
Balance at January 1, 2021		2,218,496	$	222	$	95,670,216	$	(98,885,061	)	$	(3,214,623	)
Stock-based compensation expense	—		—			561,348	—				561,348
Issuance of common stock, net of costs of $1,304,846		479,166		48		13,070,106	—				13,070,154
Net loss	—		—		—			(2,605,495	)		(2,605,495	)
Balance at March 31, 2021		2,697,662		270		109,301,670		(101,490,556	)		7,811,384
Stock-based compensation expense	—		—			399,411	—				399,411
Issuance of common stock from stock option exercises		5,618		1		45,453	—				45,454
Net loss	—		—		—			(2,290,643	)		(2,290,643	)
Balance at June 30, 2021		2,703,280	$	271	$	109,746,534	$	(103,781,199	)	$	5,965,606

	Six Months Ended June 30,
	2022			2021


Operating activities
Net loss	$	(4,407,045	)	$	(4,896,138	)
Adjustments to reconcile net loss to net cash used in operating activities:
Forgiveness of paycheck protection loan and accrued interest		—			(105,130	)
Stock-based compensation expense		747,985			960,759
Change in operating assets and liabilities:
Accounts receivable, net		(70,450	)		(175,100	)
Prepaid expenses, inventory and other assets		545,455			703,867
Accounts payable and other current liabilities		(61,975	)		(805,318	)
Accrued compensation		9,348			(394,756	)
Accrued interest expense		247,945			248,208
Net cash used in operating activities		(2,988,737	)		(4,463,608	)

Financing activities
Proceeds from issuance of common stock		7,443,969			14,375,000
Payment of common stock offering costs		(148,993	)		(1,304,846	)
Proceeds from issuance of common stock from exercise of stock options		—			45,454
Net cash provided by financing activities		7,294,976			13,115,608
Net increase in cash and cash equivalents		4,306,239			8,652,000
Cash and cash equivalents at beginning of period		9,144,710			8,068,939
Cash and cash equivalents at end of period	$	13,450,949		$	16,720,939

Non-cash financing activities
Forgiveness of paycheck protection loan and accrued interest	$	—		$	105,130

Nine Months Ended
September 30,

2017

2016

Operating activities

Net loss

$
(11,921,069
)

$
(9,221,188
)
Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense

1,404,926

1,298,279

Non-cash interest

—

120,889

Financing costs allocated to warrant liability

—

533,692

Change in fair value of warrant liability

3,354,973

198,945

Change in operating assets and liabilities:

Prepaid expenses and other assets

(59,020
)

408,030

Accounts payable and accrued expenses

1,236,986

(676,745
)
Net cash used in operating activities

(5,983,204
)

(7,338,098
)

Financing activities

Payment of bank loan

—

(4,500,000
)
Proceeds from issuance of common stock, net

7,389,101

358,023

Proceeds from issuance of common stock and warrants, net

—

13,168,802

Net cash provided by financing activities

7,389,101

9,026,825

Net increase in cash and cash equivalents

1,405,897

1,688,727

Cash and cash equivalents at beginning of period

9,007,071

8,691,155

Cash and cash equivalents at end of period

$
10,412,968

$
10,379,882

Supplemental disclosure of cash flow information

Interest paid

—

$
169,813

Non-cash financing activities

Fair value of warrants issued to placement agent

—

$
369,863

Evoke Pharma, Inc. (the “Company”) was incorporated inunder the laws of the state of Delaware in January 2007. The Company is a ~~publicly-held~~ specialty pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastroenterological disorders and disease.

Since its inception, the Company has devoted ~~substantially all of~~ its efforts to developing its sole product, ~~development, raising capital~~Gimoti® (metoclopramide) nasal spray, the first and ~~building infrastructure,~~only nasally-administered product indicated for the relief of symptoms in adults with acute and ~~has not realized revenues~~recurrent diabetic gastroparesis. On June 19, 2020, the Company received approval from the U.S. Food and Drug Administration (“FDA”) for its ~~planned principal operations.~~505(b)(2) New Drug Application (“NDA”) for Gimoti. The Company ~~does not anticipate realizing revenues for the foreseeable future.~~ launched U.S. commercial sales of Gimoti in October 2020 through its commercial partner Eversana Life Science Services, LLC (“Eversana”).

The Company’s activities are subject to the significant risks and uncertainties associated with any specialty pharmaceutical company that has ~~substantial expenditures~~launched its first commercial product, including market acceptance of the product and the potential need to obtain additional funding for ~~research and development, including funding~~ its operations.

The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and expects to continue to incur net losses for the foreseeable future until such time, if ever, that it can generate significant revenues from the sale of ~~its sole product, Gimoti™. The~~Gimoti. As of June 30, 2022, the Company ~~ended the third quarter of 2017 with~~had approximately ~~$10.4~~$13.5 million in cash and cash ~~equivalents, and the~~equivalents. The Company anticipates that it will continue to incur losses from operations due to ~~its plans to fund additional clinical development,~~commercialization activities, including manufacturing Gimoti, conducting the ~~analysis of data from the comparative exposure pharmacokinetic~~post-marketing commitment single-dose pharmacokinetics (“PK”) clinical trial ~~completion~~of Gimoti to characterize dose proportionality of a ~~planned new drug application (“NDA”) submission for Gimoti, pre-approval and pre-commercialization activities, including marketing and manufacturing~~lower dose strength of Gimoti, and ~~support its~~for other general and administrative costs to support the Company’s operations. As a result, the Company believes that there is substantial doubt about its ability to continue as a going concern for one year after the date these financial statements are issued.

The determination as to whether the Company can continue as a going concern contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In its report on the Company’s financial statements ~~for~~do not include any adjustments that may result from the year ended December 31, 2016, the Company’s independent registered public accounting firm included an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern, which contemplates the realizationoutcome of ~~assets and the satisfaction of liabilities in the normal course of business.~~ this uncertainty.

The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. The Company ~~believes~~anticipates that ~~its current cash and cash equivalents~~it will be ~~sufficient to meet estimated working capital requirements and fund operations through at least June 2018. The Company will need~~required to raise additional funds through debt, equity or ~~equity~~other forms of financing, such as potential collaboration arrangements, to fund future ~~operations.~~ operations and continue as a going concern.

There can be no assurance that additional financing will be available when needed or on acceptable terms. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, and/or suspend or curtail ~~planned programs.~~commercialization activities. Any of these actions could materially harm the Company’s business, results of operations, financial condition and future prospects. There can be no assurance that the Company will be able to successfully commercialize Gimoti. Because the Company’s business is entirely dependent on the success of Gimoti, if the Company is unable to secure additional financing, successfully commercialize Gimoti or identify and execute on strategic alternatives for Gimoti, the Company will be required to curtail all of its activities and may be required to liquidate, dissolve or otherwise wind down its operations.

The Company began its commercial sales of Gimoti with Eversana in October 2020. Due to the COVID-19 pandemic, the Company experienced disruptions to its sales activities, including its efforts to reach physicians and customers. For example, Eversana’s commercialization efforts at the time the Company launched Gimoti were adversely affected by operational restrictions imposed on its sales force from quarantines, travel restrictions and bans, and other governmental restrictions related to COVID-19. As a result of these restrictions, Eversana’s sales force was restricted from conducting in-person interactions with certain physicians and customers and was restricted to conducting Gimoti educational and promotional activities virtually in certain circumstances, which impacted Eversana’s ability to more actively market Gimoti. Starting in the fourth quarter of 2021, certain physician offices began to allow more frequent in-person interactions, which has helped to increase the educational and promotional activities of the sales force. The Company anticipates that it and Eversana will continue to be impacted by the COVID-19 pandemic to some extent.

The COVID-19 pandemic has not significantly disrupted the operations of the Company’s third-party suppliers and manufacturers or delayed the Company’s manufacturing timelines of Gimoti, but may negatively impact the Company’s ability to successfully commercialize Gimoti and generate product sales in the future. Further, the COVID-19 pandemic and related mitigation measures have also had an adverse impact on global economic conditions which could have an adverse effect on the Company’s future business and financial condition, including impairing its ability to raise capital when needed.

In March 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted in response to the COVID-19 pandemic. In April 2020, the Company applied for and was approved for a Small Business Administration (“SBA”) loan under the Paycheck Protection Program, established by the CARES Act. On May 1, 2020, the Company received the loan proceeds of approximately $104,000. In January 2021, the Company received notice that its loan and accrued interest were forgiven by the SBA.

On December 29, 2021, the Company received a letter from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market.

In accordance with Nasdaq listing rules, the Company was provided an initial period of 180 calendar days, or until June 27, 2022, to regain compliance. The letter stated that Nasdaq will provide written notification that the Company has achieved compliance with its rules if at any time before June 27, 2022 the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq letter had no immediate effect on the listing or trading of the Company’s common stock and the common stock continued to trade on The Nasdaq Capital Market.

On April 27, 2022, the Company’s stockholders granted the board of directors the authority to effect a reverse stock split of the Company’s outstanding common stock. On May 23, 2022 the Company effected a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of the Company’s issued and outstanding common stock, warrants to purchase common stock, and options to purchase common stock have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

On June 7, 2022, the Company received notice from Nasdaq stating that the closing price of the Company’s common stock had been at $1.00 per share or greater for the prior ten consecutive business days and that the Company had regained compliance with the minimum $1.00 per share requirement.

The accompanying condensed balance sheet as of December 31, ~~2016,~~2021, which has been derived from audited financial statements, and the unaudited interim condensed financial statements, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and follow the requirements of the U.S. Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair ~~presentation~~statement of the Company’s financial position and its results of operations and its cash flows for the periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company’s financial statements and accompanying notes for the year ended December 31, ~~2016,~~2021, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March ~~15, 2017.~~8, 2022. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

The Company ~~also~~ relies on contract research organizations (“CROs”) and consultants to ~~manage~~assist with ongoing regulatory activities. If the ~~analysis of data from the comparative exposure PK trial~~CROs and ~~the preparation of the planned NDA. If these CROs~~consultants are unable to continue ~~with~~their support, this ~~analysis and the management of the NDA preparation, the delays~~ could adversely affect the ~~completion and the timing of the filing of the NDA with FDA.~~Company’s operations.

In addition, the Company relies on third-party manufacturers for the production of ~~its drug candidate.~~Gimoti. If the third-party manufacturers are unable to continue manufacturing ~~the Company’s drug candidate,~~Gimoti, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for ~~its product candidate, if approved by the FDA,~~Gimoti, and the development and/or commercialization of ~~the product candidate~~Gimoti could be materially and adversely affected.

~~Warrant Accounting~~The Company also relies on a dedicated third-party sales team to sell Gimoti. If such third-party organization is unable to continue serving as a dedicated sales team, the commercialization of Gimoti could be materially and adversely affected.

~~Certain~~Accounts receivable are recorded net of allowance for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations and historical payment patterns. The allowance for doubtful accounts was 0 at June 30, 2022 and December 31, 2021 and 0 bad debt expense was recorded for the ~~warrants~~six months ended June 30, 2022 and 2021.

The Company does not own or operate manufacturing facilities for the production of Gimoti, nor does it plan to ~~purchase shares~~develop its own manufacturing operations in the foreseeable future. The Company depends on third-party contract manufacturers for all of its required raw materials, drug substance and finished product for its commercial manufacturing. The Company has agreements with Cosma S.p.A. to supply metoclopramide for the manufacture of Gimoti, and with Thermo Fisher Scientific Inc., through its subsidiary Patheon UK Limited, for the manufacturing of Gimoti. The Company currently utilizes third-party consultants, which it engages on an as-needed, hourly basis, to manage the manufacturing contractors.

Subsequent to FDA approval, the Company began manufacturing Gimoti for commercialization and began capitalizing inventory at that time. The Company’s inventory consisted of approximately $169,000 of raw materials at June 30, 2022 and $150,000 at December 31, 2021, and approximately $100,000 and $35,000 of finished goods inventory at June 30, 2022 and December 31, 2021, respectively. Inventories are stated at the lower of cost (first-in first-out basis) or net realizable value. Inventory at December 31, 2021 was written down by $30,000 due to establishing a reserve for obsoletion. The new cost basis and its value is not to be subsequently increased based upon changes in underlying facts and circumstances. The Company’s raw materials inventory is held at its third-party suppliers and its work-in-process and finished goods inventory is held at its manufacturer and at Eversana. The Company records such inventory as consigned inventory.

The Company’s ability to generate revenue and become profitable depends on its ability to successfully commercialize Gimoti, which was launched in the United States through prescription in October 2020 through the Company’s ~~common stock, issued as a part~~commercial partner Eversana. If the Company or Eversana fail to successfully grow and maintain sales of Gimoti, the ~~at-the-market registered direct offerings in July~~Company may never generate significant revenues and ~~August 2016, are classified as warrant liability~~its results of operations and recorded at fair value. These warrants contain a feature that could require the transfer of cash in the event a change of control occurs without the authorization of our Board of Directors, and therefore, are classified as a liability infinancial position will be adversely affected.

In accordance with ~~the Financial Accounting Standards Board (“FASB”)~~ Accounting Standards Codification (“ASC”) ~~480.~~

The fair value of each warrant is estimated on the date of issuance, and each subsequent balance sheet date, using the Black-Scholes valuation model using the appropriate risk-free interest rate, expected term and volatility assumptions. The expected life of the warrant was calculated using the remaining life of the warrant. Due to the Company’s limited historical data as a public company, the estimated volatility is calculated based upon the Company’s historical volatility, supplemented, as necessary,606, Revenue from Contracts with historical volatility of comparable companies in the biotechnology industry whose share prices are publicly available for a sufficient period of time. The risk-free rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the stock award being valued.

~~This warrant liability is subject to remeasurement at each balance sheet date and~~Customers, the Company recognizes ~~any change~~revenue when a customer obtains control of promised goods in an amount that reflects the consideration the Company expects to receive in exchange for the goods provided. Customer control is determined upon the customer’s physical receipt of the product. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with the customer; identify the performance obligations in the ~~fair value~~contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) it satisfies a performance obligation. At contract inception, the Company assesses the goods promised within each contract and determines those that are performance obligations and assesses whether each promised good is distinct. The Company then recognizes as revenue the amount of the ~~warrant liability~~transaction price that is allocated to the respective performance obligation when the customer obtains control of the product.

Product sales are recorded at the transaction price, which may include variable considerations for co-payment assistance to commercially insured patients meeting certain eligibility requirements, as well as to uninsured patients. Co-payment assistance is recorded as an offset to gross revenue at the time revenue from the product sale is recognized based on expected and actual program participation. Co-pay liabilities are estimated using prescribing data available from customers. Actual amounts of consideration ultimately received may materially differ from the Company’s estimates. If actual results in the ~~statement of operations. The~~future vary from estimates, the Company will ~~continue to~~ adjust ~~the carrying value of the warrants for changes~~these estimates, which would affect net product revenue and earnings in the ~~estimated fair value until~~period such variances become known. Liabilities for co-pay assistance of approximately $49,000 and $44,000 at June 30, 2022 and December 31, 2021, respectively, are classified as accounts payable and accrued expenses in the earlier of the modification, exercise or expiration of the warrants. At that time, the liabilities will be reclassified to additional paid-in capital, a component of stockholders’ equity. We anticipate that the value of the warrants could fluctuate from quarter to quarter and that such fluctuation could have a material impact on our financial statements.balance sheets.

Stock-based compensation expense for stock option grants and employee stock purchases under the Company’s Employee Stock Purchase Plan (the “ESPP”) is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the employee’s requisite service ~~period.~~period, except awards with a performance condition. Awards with a performance condition commence vesting when the satisfaction of the performance condition is probable. The estimation of stock option and ESPP fair value requires management to make estimates and judgments about, among other things, employee exercise behavior, forfeiture rates and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.

The Company grants stock options to purchase common stock to employees and members of the board of directors with exercise prices equal to the Company’s closing market price on the date the stock options are granted. The risk-free interest rate assumption was based on the yield of an applicable rate for U.S. Treasury instruments with maturities similar to those of the expected term of the award being

valued. The weighted average expected term of options and employee stock purchases was calculated using the simplified method as prescribed by accounting guidance for stock-based compensation. This decision was based on the lack of relevant historical data due to the Company’s limited historical experience. In addition, due to the Company’s limited historical data, the estimated volatility was calculated based upon the Company’s historical volatility, supplemented, as necessary, with historical volatility of comparable companies in the biotechnology industry whose share prices are publicly available for a sufficient period of time. The assumed dividend yield was based on the Company never paying cash dividends and having no expectation of paying cash dividends in the foreseeable future. The Company accounts for forfeitures as the forfeitures occur.

Research and development costs are expensed as incurred and primarily include compensation and related benefits, stock-based compensation expense, ~~and~~ costs paid to third-party contractors to perform research, conduct clinical trials and develop drug materials and delivery devices. The Company expenses costs relating to the purchase and production of pre-approval inventories as research and development expense in the period incurred until FDA approval is received.

The Company bases its expense accruals related to clinical studies on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical studies on its behalf. The financial terms

of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors, such as the successful enrollment of patients, site initiation and the completion of clinical study milestones. Service providers typically invoice the Company monthly in arrears for services performed. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the Company does not identify costs that have begun to be incurred, or if the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ materially from estimates. To date, the Company has not experienced significant changes in estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates, no assurance can be made that changes to the estimates will not be made in the future as the Company becomes aware of additional information about the status or conduct of clinical studies and other research activities.

Included in research and development expenses for the three and nine months ended September 30, 2017 were costs of approximately $8,000 and $19,000, respectively, for clinical trial services incurred by a related party of one of the Company’s officers. There were no related party costs incurred during the nine months ended September 30, 2016.

The Company does not own or operate manufacturing facilities for the production of Gimoti, nor does it plan to develop its own manufacturing operations in the foreseeable future. The Company currently depends on third-party contract manufacturers for all of its required raw materials, drug substance and finished product for its preclinical research, product development and clinical trials. The Company has agreements with Cosma S.p.A. to supply metoclopramide for the manufacture of Gimoti, and with Thermo Fisher Scientific Inc., who recently acquired Patheon UK Limited, for product development activities and drug product materials, and technology acquisition milestones. The Company will expense the clinical, regulatory and manufacturing costs related to the post-marketing commitment to conduct a single dose PK clinical trial of Gimoti to characterize dose proportionality of a lower dose strength of Gimoti, as well as other costs that may occur for any additional clinical trials the Company may pursue to expand the indication of Gimoti. ~~The Company currently utilizes a third-party consultant, which it engages on an as-needed, hourly basis, to manage product development and manufacturing contractors.~~

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding for the period, without consideration for common stock equivalents and adjusted for the weighted-average number of common stock outstanding that are subject to repurchase. The Company has excluded 45,000 shares of common stock subject to repurchase from the weighted-average number of common stock outstanding for the three and nine months ended September 30, 2017 and 2016.equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of ~~shares subject~~warrants to ~~repurchase, warrants for the~~ purchase of common stock, and options ~~outstanding~~to purchase common stock under the Company’s equity incentive ~~plans and potential shares to be purchased under the ESPP. For the periods presented, the~~plan.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be ~~anti-dilutive:~~

~~For~~anti-dilutive for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017, dilutive shares of 0~~2022 and ~~25,876, respectively, related to the outstanding warrants were included in the diluted net loss per share of common stock calculation.~~2021:

In ~~February~~June 2016, the Financial Accounting Standards Board, (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. This update is effective for annual periods beginning after December 15, 2022, and interim periods within those periods, and early adoption is permitted. The Company expects to adopt the standard on its effective date in the first quarter of 2023. The Company also believes the adoption will modify the way we analyze financial instruments, but currently do not expect the adoption to have a material financial impact on our financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options, or Subtopic 470-20 and Derivatives and Hedging—Contracts in Entity’s Own Equity, orSubtopic 815-40: Accounting ~~Standards Update (“ASU”) No. 2016-02,~~ ~~Leases. The new standard establishes a right-of-use (“ROU”) model~~for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that ~~requires a lessee~~are required for equity contracts to ~~record a ROU asset~~qualify for the derivative scope exception and ~~a lease liability on~~simplifies the ~~balance sheet for all leases with terms longer than 12 months. Leases~~diluted earnings per share, or EPS, calculation in certain areas. ASU 2020-06 will be ~~classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is~~ effective for fiscal years beginning after December 15, ~~2018,~~2023, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The ~~Company is currently evaluating the impact of its pending adoption of the new standard on the~~ Company’s ~~financial statements.~~

~~In March 2016, the FASB issued ASU No. 2016-09~~ ~~Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting~~. This guidance changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid-in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. Theearly adoption of this ~~guidance~~accounting standard on January 1, ~~2017~~2022 did not have a material impact on the Company’s financial ~~statements.~~statements and related disclosures.

The Company’s current operating lease for office space in Solana Beach, California was extended in February 2022 and has an expiration date of October 31, 2022, subject to the landlord’s option to cancel upon 30 days written notice.

As of June 30, 2022, the Company has future minimum lease payments under its existing facility lease of approximately $50,000 payable in 2022.

On ~~August 4, 2016,~~February 25, 2022, the Company ~~repaid~~received a letter notifying us that Teva Pharmaceuticals, Inc. (“Teva”) submitted to FDA an abbreviated new drug application, or ANDA, for a generic version of Gimoti (metoclopramide hydrochloride) nasal spray eq. 15 mg base/spray that contains Paragraph IV certifications with respect to two of our patents covering Gimoti, U.S. Patent Nos. 8,334,281, expiration date May 16, 2030; and 11,02,0361, expiration date December 22, 2029. These patents are listed in ~~full~~FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the ~~entire $4.5 million~~Orange Book, for Gimoti. The certifications allege these patents are invalid or will not be infringed by the manufacture, use or sale of ~~outstanding principal and interest under the Loan and Security Agreement (the “Loan Agreement”) between~~Teva’s metoclopramide hydrochloride nasal spray eq. 15 mg base/spray. In April 2022, the Company initiated litigation in the United States District Court for the District of New Jersey, alleging that Teva infringes the patents covering Gimoti. Teva has denied all material allegations and ~~Square 1 Bank (“Square 1”). In~~asserted counterclaims of non-infringement and invalidity. The Company has not recorded any loss in connection with ~~such repayment, the Loan Agreement was terminated, and all security, liens or other encumbrances on assets of the Company were released.~~this matter because it believes that a loss is neither probable nor estimable at this time.

The Company incurred $82,685 of loan origination costs related to this credit facility. The remaining unamortized costs of approximately $38,000 were charged to interest expense upon the payment of the loan in August 2016.

In connection with the funding of the term loan, the Company issued to Square 1 a warrant to purchase 22,881 shares of the Company’s common stock at an exercise price of $5.90 per share, the closing price of the Company’s common stock on the day of funding of the credit facility. During July 2016, Square 1 converted its warrant by a “cashless” conversion and received 9,887 shares of the Company’s common stock. The value determined for the warrant at the time of the grant of $108,122 was recorded as a debt discount, as well as to stockholders’ equity. The remaining unamortized debt discount associated with the warrant of approximately $59,000 was charged to interest expense upon the payment of the loan in August 2016.

In June 2007, the Company acquired all worldwide rights, data, patents and other related assets associated with Gimoti from Questcor Pharmaceuticals, Inc. (“Questcor”) pursuant to an ~~Asset Purchase Agreement.~~asset purchase agreement. The Company paid Questcor $650,000 in the form of an upfront payment and $500,000 in May 2014 as a milestone payment based upon the initiation of the first patient dosing in the Company’s Phase 3 clinical trial for Gimoti. In August 2014, Mallinckrodt, plc (“Mallinckrodt”) acquired Questcor. As a result of that acquisition, Questcor transferred its rights included in the ~~Asset Purchase Agreement~~asset purchase agreement with the Company to Mallinckrodt. In addition to the payments previously made to Questcor, the Company may also be required to make additional milestone payments totaling up to ~~$51.5~~$52 million. ~~These milestones include up~~In March 2018, the Company and Mallinckrodt amended the asset purchase agreement to ~~$4.5 million in~~defer development and approval milestone payments, ~~if Gimoti achieves the following development targets:~~

The remaining $47 million in milestone payments depend on Gimoti’s commercial ~~success and will only apply if Gimoti receives regulatory approval. In addition, the~~success. The Company ~~will be~~is required to pay to Mallinckrodt a low single digit royalty percentage on net sales of Gimoti. As of June 30, 2022, the Company has paid Mallinckrodt approximately $82,000 in royalties on net sales of Gimoti. The Company’s obligation to pay such royalties will terminate upon the expiration of the last patent right covering Gimoti, which is expected to occur in ~~2030.~~2030, subject to possible extension should any additional, later expiring, licensed patents be granted.

On July 25, 2016, the Company completed a registered direct offering of 1,804,512 shares of common stock at a purchase price of $2.49375 per share (the “July 2016 Financing”). Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received from the Company an unregistered warrant to purchase three-quarters of a share of common stock, for a total of 1,353,384 shares (the “July Warrants”). The July Warrants have an exercise price of $2.41 per share, are immediately exercisable and will expire on January 25, 2022. The aggregate gross proceeds from the sale of the common stock and warrants were $4.5 million, and the net proceeds after deduction of commissions and fees were $4.0 million.

In connection with the July 2016 Financing, the Company issued to its placement agent, Rodman & Renshaw, a unit of H.C. Wainwright & Co. LLC (“Wainwright”), and its designees unregistered warrants to purchase an aggregate of 90,226 shares of the Company’s common stock (the “July Wainwright Warrants”). The July Wainwright Warrants have substantially the same terms as the July Warrants, except that the July Wainwright Warrants will expire on July 21, 2021 and have an exercise price equal to $3.1172 per share of common stock.

On August 3, 2016, the Company completed a registered direct offering of 3,244,120 shares of common stock at a purchase price of $3.0825 per share (the “August 2016 Financing”) and together with the July 2016 Financing (the “2016 Financings”). Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received from the Company an unregistered warrant to purchase one half of a share of common stock, for a total of 1,622,060 shares (the “August Warrants”). The August Warrants have an exercise price of $3.03 per share, are immediately exercisable and will expire on February 3, 2022. The aggregate gross proceeds from the sale of the common stock and warrants were $10 million, and the net proceeds after deduction of commissions and fees was approximately $9.2 million.

In connection with the August 2016 financing, the Company issued to its placement agent, Wainwright, and its designees unregistered warrants to purchase an aggregate of 162,206 shares of the Company’s common stock (the “August Wainwright Warrants”). The August Wainwright Warrants have substantially the same terms as the August Warrants, except that the August Wainwright Warrants will expire on July 29, 2021 and have an exercise price equal to $3.853125 per share of common stock.

The warrants issued in connection with the 2016 Financings had a total initial fair value of $4,899,459 on their respective closing dates as determined using the Black Scholes pricing model and such value was recorded as the initial carrying value of the warrant liability. The fair value of the warrants is remeasured at each financial reporting period with any change in fair value recognized as a change in fair value of the warrant liability in the Statement of Operations.

On December 15, 2016, the Company entered into amendments (the “Warrant Amendments”) with certain of the holders (the “Holders”) of the Company’s outstanding warrants to purchase common stock issued on July 25, 2016 and August 3, 2016. Pursuant to the Warrant Amendments, the Holders’ right to require the Company to purchase the outstanding warrants upon the occurrence of certain fundamental transactions will not apply if the fundamental transaction is a result of a transaction that has not been approved by the Company’s board of directors. As a result of this amendment, warrants to purchase 252,432 shares of the Company’s common stock were no longer required to be classified as liabilities. The value of amended warrants were adjusted to their fair value immediately prior to the amendment and approximately $207,000 was reclassified from warrant liability to Additional Paid-in Capital.

On February 16, 2017, an institutional investor from the Company’s financing which closed in July 2016 converted its warrant to purchase 526,315 shares of our common stock by a “cashless” exercise and received 211,860 shares of the Company’s common stock. The warrant had an exercise price of $2.41 per share. The shares were issued, and the warrants were sold, in reliance upon the registration exemption set forth in Section 4(a)(2) of the Securities Act of 1933, as amended. The value of the exercised warrants were adjusted to their fair value immediately prior to the exercise and approximately $1.4 million was reclassified from warrant liability to Additional Paid-in Capital. Subsequent to this transaction, warrants to purchase 2,449,129 shares of the Company’s common stock remain classified as a liability.

In ~~February and March 2017,~~January 2021, the Company completed the sale of ~~2,775,861~~479,166 shares of its common stock in an underwritten public offering led by Laidlaw & Company (UK) Ltd. The price to the public in this offering was ~~$2.90~~$30.00 per share resulting in gross proceeds to the Company of approximately ~~$8.0~~$14.4 million. After deducting underwriting discounts and commissions and ~~estimated~~ offering expenses ~~payable~~paid by the Company, the net proceeds to the Company raised from this offering ~~was~~were approximately ~~$7.3~~$13.1 million.

On April 15, 2016, the Company terminated its At Market Sales Agreement with MLV & Co. LLC and entered into a new At Market Issuance Sales Agreement with B. Riley FBR, Inc. (as successor by merger to FBR Capital Markets & Co., “FBR”) (“FBR Sales Agreement”), and filed a prospectus supplement, pursuant to which the Company may sell from time to time, at its option, up to an aggregate of 649,074 shares of the Company’s common stock through FBR as the sales agent. The sales of shares made through this equity program are made in “at-the-market” offerings as defined in Rule 415 of the Securities Act. Through December 31, 2016, the Company sold 56,000 shares of common stock at a weighted average price per share of $5.45 and received proceeds of approximately $296,000, net of commissions and fees.

~~On March 10,~~In November 2017, the Company filed a ~~prospectus supplement, which replaced~~shelf registration with the ~~prospectus supplement filed on April 15, 2016, permitting the Company to sell up to an aggregate of $20.0 million of shares of its common stock through FBR as a sales agent. Under current~~ SEC ~~regulations, if at the time the Company files its Annual Report~~ on Form 10-K, or Form 10-K, the Company’s public float is less than $75 million, and for so long as its public float remains less than $75 million, the amount the Company can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of the Company’s public float, which is referred to as the baby shelf rules. As of November 3, 2017, the Company’s public float was approximately $49.9 million, based on 12,858,418 shares of outstanding common stock held by non-affiliates and at a price of $3.88 per share, which was the last reported sale price of the Company’s common stock onS-3. The ~~Nasdaq~~

Capital Market on October 11, 2017. As a result of the Company’s public float being below $75 million, the Company will be limited by the baby shelf rules until such time as the Company’s public float exceeds $75 million, which means the Company only has the capacity to sell shares up to one-third of its public float under shelf registration statements in any twelve-month period. The Company had no sales of common stock under the baby shelf rules in the twelve-month period ended November 3, 2017. ~~If the Company’s public float decreases, the amount of securities we may sell under our Form S-3~~ shelf registration statement ~~will also decrease.~~ ~~The Company has not sold any shares of common stock through the FBR Sales Agreement during 2017.~~

The Company’s current Form S-3 shelf registration statement expires on November 25, 2017. Concurrently with filing this Quarterly Report on Form 10-Q, the Company is filing a new shelf registration statement on Form S-3 which extends the effectiveness of the current shelf registration statement until the earlier of the date the SEC declares the new shelf registration statement effective or 6 months from the expiration date of the current shelf registration statement. The new shelf registration statement includesincluded a prospectus for the at-the-market offering to sell up to an aggregate of $16.0 million of shares of the Company’s common stock through B. Riley FBR, Inc. (“FBR”) as a sales ~~agent.~~agent (the “FBR Sales Agreement”). Effective January 6, 2021, the Company terminated the FBR Sales Agreement. As a result, there were 0 shares sold under the FBR Sales Agreement during 2021.

In December 2020, the Company filed a new shelf registration statement with the SEC on Form S-3, or the replacement shelf registration statement. The replacement shelf registration statement replaced the registration statement on Form S-3 the Company ~~remains subject~~originally filed with the SEC in November 2017, which registration statement expired in December 2020. The replacement shelf registration was declared effective by the SEC on January 6, 2021. In December 2020, the Company also entered into a new At Market Issuance Sales Agreement (the “ATM Sales Agreement”), with FBR and H.C. Wainwright & Co. (together with FBR, the “Sales Agents”), pursuant to which the Company may sell from time to time, at its option, up to an aggregate of $30 million worth of shares of the Company’s common stock through the Sales Agents. The ATM Sales Agreement provides, among other things, that sales under the ATM Sales Agreement will be made pursuant to the ~~limitations~~registration statement, including the base prospectus filed as part of such registration statement. During the ~~baby shelf rules described above.~~third quarter of 2021, the Company sold 18,091 shares of common stock at a weighted-average price per share of $17.64 pursuant to the ATM Sales Agreement and received proceeds of approximately $313,000, net of commissions and fees. During the three months ended March 31, 2022, the Company sold 21,783 shares of common stock at a weighted-average price

per share of $8.04 pursuant to the ATM Sales Agreement and received proceeds of approximately $172,000, net of commissions and fees. During the three months ended June 30, 2022, the Company sold 599,914 shares of common stock at a weighted-average price per share of $12.12 pursuant to the ATM Sales Agreement and received proceeds of approximately $7.1 million, net of commissions and fees.

Future sales under the ATM Sales Agreement will depend on a variety of factors including, but not limited to, market conditions, the trading price of the Company’s common stock and the Company’s capital needs. There can be no assurance that ~~FBR~~the Sales Agents will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that the Company deems appropriate.

In addition, the Company will not be able to make future sales of common stock pursuant to the ~~FBR~~ATM Sales Agreement unless certain conditions are met, which include the accuracy of representations and warranties made to ~~FBR~~the Sales Agents under the ~~FBR~~ATM Sales Agreement. Furthermore, ~~FBR~~each of the Sales Agents is permitted to terminate the ~~FBR~~ATM Sales Agreement with respect to itself in its sole discretion upon ten days’ notice, or at any time in certain circumstances, including the occurrence of an event that would be reasonably likely to have a material adverse effect on the Company’s assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders’ equity or results of operations. The Company has no obligation to sell the ~~remaining~~ shares available for sale pursuant to the ~~FBR~~ATM Sales Agreement.

~~As a result~~The Company has issued warrants to purchase common stock to banks that have previously loaned funds to the Company, as well as to representatives of ~~payroll withholdings from~~the underwriters of the Company’s ~~employees~~public offerings and certain of ~~approximately $135,000~~their affiliates.

During 2021, there were 0 warrants exercised and ~~$99,000, the Company sold 75,529 and 34,067~~warrants to purchase 13,517 shares of common stock ~~through its Employee Stock Purchase Plan (“ESPP”) during~~expired. During the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2022, there were 0 warrants exercised and ~~2016, respectively.~~

~~On May 3, 2017, the Company’s stockholders approved an amendment and restatement of the Company’s ESPP~~warrants to ~~increase the number of~~purchase 139,972 shares of common stock ~~reserved under the ESPP by 100,000~~expired. At June 30, 2022, there were 0 warrants outstanding to purchase shares ~~(to an aggregate~~ of ~~1,250,000 shares),~~common stock. At December 31, 2021, there were warrants outstanding to ~~increase the annual evergreen provision from 30,000~~purchase 139,972 shares ~~to 100,000 shares, and to extend the term~~ of ~~the ESPP into 2027.~~common stock with a weighted average exercise price of $34.80.

Stock-based compensation expense includes charges related to ~~stock option grants under the Company’s 2016 Equity Incentive Award Plan and~~ employee stock purchases under the ~~ESPP.~~ESPP and stock option grants. The Company measures stock-based compensation expense based on the grant date fair value of any awards granted to its employees. Such expense is recognized over the period of time that employees provide service and earn rights to the awards.

During the six months ended June 30, 2022 and 2021, the Company granted stock options to purchase 78,247 and 140,167 shares of the Company’s common stock, respectively. The estimated fair value of each stock option award granted was determined on the date of grant using the ~~Black Scholes~~Black-Scholes option-pricing valuation model with the following ~~weighted-average~~ assumptions for option grants during the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2022 and ~~2016:~~2021:

The estimated fair value of the shares to be acquired under the ESPP was determined on the initiation date of each six-month purchase period using the Black-Scholes option-pricing valuation model with the following assumptions for ESPP shares to be purchased during the three and six months ended June 30, 2022 and 2021:

There were no ~~stock options granted~~employee withholdings to purchase shares during the ~~three months ended~~six-month purchase period beginning September ~~30, 2017~~1, 2021 and ~~2016.~~

The estimated fair value of each ESPP award was determined on the date of grant using the Black Scholes option-pricing valuation model with the following weighted-average assumptions for option grants during the three and nine months ended September 30, 2017 and 2016:

The Company recognized ~~non-cash~~ stock-based compensation expense to employees and directors in its research and development and its selling, general and administrative functions during the three and six months ended June 30, 2022 and 2021 as follows:

As of ~~September~~June 30, ~~2017,~~2022, there ~~were~~was approximately ~~$2.1~~$2.5 million of unrecognized compensation costs related to outstanding employee and board of director options, which are expected to be recognized over a ~~weighted average~~weighted-average period of ~~1.2~~1.17 years.

6. ~~Fair Value Measurements~~Commercial Services and Loan Agreements with Eversana

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

~~As noted in Note 5, during the third quarter of 2016~~In January 2020, the Company entered into ~~the 2016 Financings~~a commercial services agreement (the “Eversana Agreement”) with ~~an institutional investor providing~~Eversana for the ~~issuance~~commercialization of Gimoti. Pursuant to the Eversana Agreement, Eversana commercializes and ~~sale~~distributes Gimoti in the United States. Eversana also manages the marketing of Gimoti to targeted health care providers, as well as the sales and distribution of Gimoti in the United States.

Under the terms of the Eversana Agreement, the Company maintains ownership of the Gimoti NDA, as well as legal, regulatory, and manufacturing responsibilities for Gimoti. Eversana will utilize its internal sales organization, along with other commercial functions, for market access, marketing, distribution and other related patient support services. The Company will record sales for Gimoti and retain more than 80% of net product profits once the parties’ costs are reimbursed. For the three months ended June 30, 2022 and 2021, approximately $368,000 and $192,100 of Eversana profit sharing costs were included as selling, general and administrative costs, respectively. For the six months ended June 30, 2022 and 2021, approximately $716,000 and $268,000 of Eversana profit sharing costs were included as selling, general and administrative costs, respectively. As of June 30, 2022, unreimbursed commercialization costs to Eversana were approximately $38.4 million. Such costs will generally be payable only as net product profits are recognized. Eversana will receive reimbursement of its commercialization costs pursuant to an agreed upon budget and a percentage of product profits in the mid-to-high teens. Net product profits are the net sales (as defined in the Eversana Agreement) of Gimoti, less (i) reimbursed commercialization costs, (ii) manufacturing and administrative costs set at a fixed percentage of net sales, and (iii) third party royalties. During the term of the Eversana Agreement, Eversana agreed to not market, promote, or sell a competing product in the United States. On February 1, 2022, the Eversana Agreement was amended (the “Amended Eversana Agreement”) to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms. This amendment also increased the percentage of net product profit retained by the Company and increased the proportion of ~~5,048,632 shares~~costs that are reimbursed to Eversana to the extent Eversana has accumulated unreimbursed costs.

Upon expiration or termination of the agreement, the Company will retain all profits from product sales and assume all corresponding commercialization responsibilities. Within 30 days after each of the first three annual anniversaries of commercial launch, either party may terminate the agreement if net sales of Gimoti do not meet certain annual thresholds. Either party may terminate the agreement: for the material breach of the other party, subject to a 60-day cure period; in the event an insolvency, petition of the other party is pending for more than 60 days; upon 30 days written notice to the other party if Gimoti is subject to a safety recall; the other party is in breach of certain regulatory compliance representations under the agreement; if the Company discontinues the development or production of Gimoti; if the net profit is negative for any two consecutive calendar quarters beginning with the first full calendar quarter 24 months following commercial launch; if the cumulative net product profits fail to reach certain thresholds in the first three years following launch; or if there is a change in applicable laws that makes operation of the services as contemplated under the agreement illegal or commercially impractical. Either party may also terminate the Amended Eversana Agreement upon a change of control of the Company’s ~~common stock~~ownership. In the event that the Company initiates such termination, the Company shall pay to Eversana a one-time payment equal to all of Eversana’s unreimbursed cost plus a portion of Eversana’s commercialization costs incurred in the 12 months prior to termination. Such payment amount would be reduced by the amount of previously reimbursed commercialization costs and ~~warrants~~profit split paid for the related prior twelve-month period and any revenue which occurred prior to ~~purchase~~the termination yet to be collected. If Eversana terminates the agreement due to an uncured material breach by the Company, or if the Company terminates the Eversana Agreement in certain circumstances, the Company has agreed to reimburse Eversana for its unreimbursed commercialization costs for

the prior twelve-month period and certain other costs. In addition, Eversana may terminate the Eversana Agreement if the Company withdraws Gimoti from the market for more than 90 days.

In connection with the Eversana Agreement, the Company and Eversana have entered into the Eversana Credit Facility, pursuant to which Eversana has agreed to provide a revolving Credit Facility of up to ~~2,975,444 shares~~$5 million to the Company upon FDA approval of the Gimoti NDA under certain customary conditions. The Eversana Credit Facility terminates on June 25, 2025, unless terminated earlier pursuant to its terms. The Eversana Credit Facility is secured by all of the Company’s ~~common stock for aggregate gross proceeds~~personal property other than the Company’s intellectual property. Under the terms of ~~$14.5 million. In addition, as partial payment for services,~~the Eversana Credit Facility, the Company ~~issued~~cannot grant an interest in the Company’s intellectual property to any other person. Each loan under the ~~underwriters warrants~~Eversana Credit Facility will bear interest at an annual rate equal to ~~purchase up to 252,432 shares~~10.0%, with such interest due at the end of the ~~Company’s common stock.~~loan term. In 2020 the Company borrowed $5 million under the Eversana Credit Facility.

The Company ~~utilizes a valuation hierarchy for disclosure~~may prepay any amounts borrowed under the Eversana Credit Facility at any time without penalty or premium. The maturity date of all amounts, including interest, borrowed under the Eversana Credit Facility will be 90 days after the expiration or earlier termination of the ~~inputs~~Eversana Agreement. The Eversana Credit Facility also includes events of default, the occurrence and continuation of which provide Eversana with the right to exercise remedies against the ~~valuations used~~Company and the collateral securing the loans under the Eversana Credit Facility, including the Company’s cash. These events of default include, among other things, the Company’s failure to ~~measure fair value. This hierarchy prioritizes~~pay any amounts due under the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full termEversana Credit Facility, an uncured material breach of the ~~financial instrument. Level 3 inputs are unobservable inputs based on~~representations, warranties and other obligations under the ~~Company’s own assumptions used to measure assets~~Eversana Credit Facility, the occurrence of insolvency events and ~~liabilities at fair value. A financial asset or liability’s classification within~~ the ~~hierarchy is determined based on the lowest level input that is significant to the fair value measurement.~~

~~The Company had no assets or liabilities classified as Level 1 or Level 2. The warrant liability is classified as Level 3.~~occurrence of a change in control.

The Company has classified the warrants as a liability and has remeasured the liability to estimated fair value at September 30, 2017 and December 31, 2016, using the Black Scholes option pricing model with the following assumptions:

The following fair value hierarchy table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016:

The following table presents a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended September 30, 2017:

~~There were no transfers between Level 1 and Level 2 in any of the periods reported.~~

I~~tem~~Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto for the fiscal year ended December 31, ~~2016~~2021 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March ~~15, 2017.~~8, 2022. Past operating results are not necessarily indicative of results that may occur in future periods.

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, ~~prospective products, product approvals,~~commercial activities to be conducted by Eversana Life Science Services, LLC, or Eversana, the pricing and reimbursement for Gimoti, future regulatory developments, research and development costs, the timing and likelihood of commercial success, the potential to develop future product candidates, plans and objectives of management for future operations, ~~and~~ future results of current and anticipated products and the impact of the COVID-19 pandemic, on us or on third parties on whom we rely, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statement. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q completely. As a result of many factors, including without limitation those set forth under “Risk Factors” under Item 1A of Part II below, and elsewhere in this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in these forward-looking statements. Except as required by applicable law, we undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

We use our registered trademark, EVOKE PHARMA, and ~~our trademarked product name, Gimoti,~~other trademarks, including GIMOTI and EvokeAssist, in this Quarterly Report on Form 10-Q. This Quarterly Report on Form 10-Q also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Quarterly Report on Form 10-Q appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “Evoke,” “we,” “us” and “our” refer to Evoke Pharma, Inc.

WeWe are a specialty pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders and diseases. ~~We are~~Since our inception, we have devoted our efforts to developing our sole product, Gimoti ~~an investigational metoclopramide~~(metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms ~~associated~~in adults with acute and recurrent diabetic gastroparesis. In June 2020, we received approval from the U.S. Food and Drug Administration, or FDA, for our 505(b)(2) New Drug Application, or NDA, for Gimoti. We launched commercial sales of Gimoti in the United States in October 2020 through our commercial partner Eversana.

Diabetic gastroparesis is a ~~gastrointestinal~~GI disorder ~~afflicting~~affecting millions of ~~people~~patients worldwide, ~~and~~ ~~is characterized by slow or delayed gastric emptying and evidence~~in which food in an individual’s stomach takes too long to empty resulting in a variety of ~~gastric retention in the absence of mechanical obstruction and can cause various~~ serious ~~digestive system~~GI symptoms and ~~other~~systemic metabolic complications. ~~Metoclopramide tablets~~The gastric delay caused by gastroparesis can compromise absorption of orally administered medications.

In January 2020, we entered into an agreement with Eversana, or the Eversana Agreement, for the commercialization of Gimoti. Pursuant to the Eversana Agreement, Eversana commercializes and ~~injection are the only products currently approved~~distributes Gimoti in the United ~~States~~States. Eversana also manages the marketing of Gimoti to ~~treat~~targeted health care providers, as well as the ~~symptoms associated with acute~~sales and ~~recurrent diabetic gastroparesis. Gimoti is a novel nasal spray formulation of metoclopramide and designed to provide systemic delivery of the molecule through the nasal mucosa.~~

~~In July 2016, we announced results from a Phase 3 clinical trial~~distribution of Gimoti in ~~female subjects with symptoms associated with acute and recurrent diabetic gastroparesis. The trial~~the United States. Eversana also provided a $5 million revolving credit facility, or the Eversana Credit Facility, that became available upon FDA approval of the Gimoti NDA. In 2020 we borrowed $5 million under the Eversana Credit Facility. On February 1, 2022, the Eversana Agreement was ~~a multicenter, randomized, double-blind, placebo-controlled, parallel group clinical trial~~amended (the “Amended Eversana Agreement”) to ~~evaluate~~extend the efficacy, safety and population pharmacokinetics, or PK, of Gimoti in adult female subjects with diabetic gastroparesis. Subjects received either Gimoti or placebo four times daily for 28 days. The primary endpoint was the change in symptomsterm from June 19, 2025 (five years from the ~~baseline period~~date the Food & Drug Administration approved the Gimoti new drug application) to ~~Week 4 as measured using a proprietary Patient Reported Outcome, or PRO, instrument. On a daily basis, subjects reported~~December 31, 2026, unless terminated earlier pursuant to its terms. This amendment also increased the ~~frequency~~percentage of net product profit retained by us and ~~severity~~increased the proportion of ~~their gastroparesis signs and symptoms using a telephone diary. The subjects’ daily symptom scores were~~costs that are reimbursed to Eversana to the basis for calculating their weekly scores using the PRO instrument. A total of 205 subjects were randomized in this trial. Preliminary results of the trial showed that Gimoti did not achieve its primary endpoint of symptom improvement at Week 4 in the intent to treat, or ITT, population.extent Eversana has accumulated unreimbursed costs.

Although the Phase 3 trial failed to reach its primary endpoint, Gimoti demonstrated efficacy in patients with moderate to severe symptoms at baseline, which included 105 of the 205 patients (51%) enrolled in the study. In these patients with higher symptom severity, statistically significant benefits were demonstrated for those treated with Gimoti versus those receiving placebo. These statistically significant benefits were observed at Weeks 1, 2 and 3 in the ITT population and at all four weeks in the per protocol population. There were also clinically and statistically significant improvements in nausea and upper abdominal pain, two of the more severe and debilitating symptoms of gastroparesis, at all four weeks.

In December 2016, we announced we had completed a second pre-new drug application, or NDA, meeting with FDA, in which FDA agreed that a comparative exposure PK trial was acceptable as a basis for submission of a Gimoti NDA. The comparative exposure PK trial will serve as a portion of the 505(b)(2) NDA submission that will include prior efficacy and safety data developed by us along with FDA’s prior findings of safety and efficacy for the Listed Drug, Reglan Tablets. In March 2017, we met with FDA to discuss the design of the comparative exposure PK trial and certain other chemistry, manufacturing and controls related items associated with the proposed NDA submission.

On October 23, 2017, we announced positive topline results from the comparative exposure PK trial. The objective of the trial was to determine the bioequivalent dose of Gimoti compared to the Reglan Tablets after nasal and oral administration to healthy volunteers under fasted conditions. Based on these results, we expect to submit the Gimoti NDA to FDA in the first quarter of 2018.

The comparative exposure PK trial was an open label, 4-way crossover and enrolled 108 male and female healthy volunteers who were each to receive one Reglan Tablet dose and three different doses of Gimoti in a random sequence. Following discussions at pre-NDA meetings with FDA, we planned to select a Gimoti dose based on criteria that includes a 90% confidence interval for the ratio of area under the plasma concentration curve, or AUC, falling within the bioequivalence range of 80-125% of Reglan Tablets. Though only one dose was needed to meet the dose selection criteria, the comparative exposure PK trial was designed to test three different strengths of Gimoti. Based on results of the study, two of the three doses tested met the dose selection criteria. The maximum observed plasma concentration, or C_max_,for Gimoti was slightly lower than the bioequivalence range, but in line with expectations that had been previously discussed with FDA as a likely outcome given the different route of administration and prior Gimoti PK trial results. Additionally, data showed the AUC and C_max increased in a dose related manner across all three strengths tested. Relative to safety, all Gimoti doses were well tolerated with no clinically significant adverse events reported following any of the doses.

~~We have no products approved for sale, and we have not generated any revenue from product sales or other arrangements.~~ We have primarily funded our operations through the sale of our convertible preferred stock prior to our initial public offering in September 2013, borrowings ~~under our bank~~from loans and the sale of shares of our common stock on the ~~NASDAQ~~Nasdaq Capital Market. We launched commercial sales of Gimoti in late October 2020 with Eversana and, to date, have generated modest sales, which we believe is partly because the launch occurred during the COVID-19 pandemic.

We have incurred losses in each year since our inception. ~~Substantially all of our~~These operating losses resulted from expenses incurred in connection with advancing Gimoti through development activities, pre-commercial and commercialization activities, and other general and administrative costs associated with our operations. We expect to continue to incur ~~significant expenses and increasing~~ operating losses ~~for at least the next several years.~~until revenues from sales of Gimoti exceed our expenses, if ever. We may never become profitable, or if we do, we may not be able to sustain profitability on a recurring basis.

As of ~~September~~June 30, ~~2017~~2022, we had cash and cash equivalents of approximately ~~$10.4~~$13.5 million. Current cash on hand is intended to fund commercialization activities for Gimoti, including manufacturing Gimoti, conducting the post-marketing commitment single dose pharmacokinetics, or PK, clinical trial of Gimoti to characterize dose proportionality of a lower dose strength of Gimoti and any additional development activities should we seek additional indications, protecting our intellectual property portfolio and for other general and administrative costs to support our operations. Our operations have consumed substantial amounts of cash since inception. We believe, based on our current operating plan, that our existing cash and cash equivalents as of June 30, 2022, as well as cash flows from future net sales of Gimoti, will be sufficient to fund our operations ~~through at least June 2018. Current~~into the second quarter of 2023. This period could be shortened if there are any significant increases in planned spending other than anticipated. We anticipate that we will be required to raise additional funds in order to continue as a going concern. Because our business is entirely dependent on ~~hand~~the success of Gimoti, if we are ~~intended~~unable to ~~fund clinical~~secure additional financing or identify and execute on other development ~~pre-approval and pre-commercialization activities~~or strategic alternatives for Gimoti or our company, we will be required to curtail all of our activities and may be required to liquidate, dissolve or otherwise wind down our operations. Any of these events could result in a complete loss of your investment in our securities.

We began our commercial sales of Gimoti with Eversana in October 2020. Due to the COVID-19 pandemic, we have experienced disruptions to our sales activities, including our efforts to reach physicians and customers. For example, Eversana’s commercialization efforts at the ~~analysis~~time we launched Gimoti were adversely affected by operational restrictions imposed on its sales force from quarantines, travel restrictions and bans, and other governmental restrictions related to COVID-19. As a result of ~~data~~these restrictions, their sales force was restricted from conducting in-person interactions with certain physicians and customers and was restricted to conducting Gimoti educational and promotional activities virtually in certain circumstances, which impacted Eversana’s ability to more actively market Gimoti. Starting in the ~~comparative exposure PK trial,~~fourth quarter of 2021, certain physician offices began to allow more frequent in-person interactions, which has increased the ~~planned NDA submission,~~educational and promotional activities of the sales force. We anticipate that we and Eversana will continue to be impacted by the COVID-19 pandemic to some extent.

The COVID-19 pandemic has not significantly disrupted the operations of our third-party suppliers and manufacturers or delayed our manufacturing timelines of Gimoti, but may negatively impact our ability to successfully commercialize Gimoti and generate product sales in the future. Further, the COVID-19 pandemic and mitigation measures have also had an adverse impact on global economic conditions which could have an adverse effect on our future business and financial condition, including impairing our ability to raise capital when needed.

In March 2020, the Coronavirus Aid, Relief, and Economic Security, or CARES, Act was enacted in response to the COVID-19 pandemic. In April 2020, we applied for ~~working capital~~ and ~~general corporate purposes.~~ were approved for a Small Business Administration, or SBA, loan under the Paycheck Protection Program, or PPP, established by the CARES Act. On May 1, 2020, we received the loan proceeds of approximately $104,000. In January 2021, we received notice that our loan and accrued interest were forgiven by the SBA.

In June 2007, we acquired all worldwide rights, data, patents and other related assets associated with Gimoti from Questcor Pharmaceuticals, Inc., or Questcor, pursuant to an asset purchase agreement. We paid Questcor $650,000 in the form of an upfront payment and $500,000 in May 2014 as a milestone payment based upon the initiation of the first patient dosing in our Phase 3 clinical trial for Gimoti. In August 2014, Mallinckrodt, plc, or Mallinckrodt, acquired Questcor. As a result of that acquisition, Questcor transferred its rights included in the asset purchase agreement with us to Mallinckrodt. In addition to the payments wepreviously made to Questcor, we may ~~also~~ be required to make additional milestone payments ~~to Mallinckrodt~~ totaling up to ~~$51.5~~$52 million. ~~These milestones include up~~In March 2018, we and Mallinckrodt amended the asset purchase agreement to ~~$4.5 million in~~defer development and approval milestone payments, ~~if Gimoti achieves the following development targets:~~

The remaining $47 million in milestone payments depend on Gimoti’s commercial ~~success and will only apply if Gimoti receives regulatory approval. In addition, we will be~~success. We are also required to pay to Mallinckrodt a low single digit royalty percentage on net sales of Gimoti. As of June 30, 2022, we have paid Mallinckrodt approximately $82,000 for

royalties on net sales of Gimoti. Our obligation to pay such royalties will terminate upon the expiration of the last patent right covering Gimoti, which is expected to occur in ~~2030.~~ 2030, subject to possible extension should any additional, later expiring, licensed patents be granted.

Our ability to generate revenue and become profitable depends on our ability to successfully commercialize Gimoti, which we launched in the United States through prescription in October 2020 through our commercial partner Eversana. If we or Eversana fail to successfully launch Gimoti and grow and maintain sales, we may never generate significant revenues and our results of operations and financial position will be adversely affected.

In accordance with Accounting Standards Codification, or ASC, 606, Revenue from Contracts with Customers, we recognize revenue when a customer obtains control of promised goods in an amount that reflects the consideration we expect to receive in exchange for the goods provided. Customer control is determined upon the customer’s physical receipt of the product. To determine revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps: identify the contracts with the customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) it satisfies a performance obligation. At contract inception, we assess the goods promised within each contract and determine those that are performance obligations and assess whether each promised good is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the customer obtains control of the product.

Co-pay liabilities are estimated using prescribing data available from customers. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

Liabilities for co-pay assistance are classified as accounts payable and accrued expenses in the balance sheets.

Gimoti prescription revenues continue to increase on several metrics. Net product sales during the second quarter of 2022 were approximately $462,000 compared to net product sales of approximately $418,000 during the first quarter of 2022, an increase of 11%. vitaCare Prescription Services, or vitaCare, the pilot program that began in February 2022, is now the primary prescription intake system used for Gimoti. vitaCare is a technology and services platform that helps physicians electronically prescribe Gimoti and helps patients navigate key access and adherence barriers for brand medications. Specifically, vitaCare helps patients understand coverage and identify available savings opportunities, and facilitates communications between providers and payors. The platform also offers a seamless path for filling a prescription. In April 2022, GoodRx announced the completion of their previously announced acquisition of vitaCare.

There were over 500 new inbound prescriptions into both the vitaCare and EvokeAssist reimbursement center during the quarter ended June 2022, a 24% increase compared to the prior quarter. Patients that have an opportunity to refill the product (that is, patients who have completed their current supply and have additional refills on their prescription) received a refill approximately 67% of the time since the launch of Gimoti. We believe some patients choose not to refill their prescriptions due to remission of symptoms. Cumulatively, new prescribing physicians increased 23% during the second quarter.

The EvokeAssist team has been able to access the Medicare and Medicaid systems, respectively, to allow for reimbursement submission of products for patients seeking treatment. For the quarter ended June 30, 2022, these government programs made up approximately 37% of the filled prescriptions for Gimoti. Through June 30, 2022, the patients have been mostly between the ages of 31-65. The vast majority of patients are female and were being treated by a gastroenterologist.

The feedback from the Eversana sales organization continues to be positive with regard to physician interest. Although many target physician offices have only recently been allowing face to face visits by sales team members, meetings with gastroenterology teams continue to generate positive enrollments and fills. Since product launch, it has taken an average of four to five physician calls before a physician writes their first prescription, which is lower than we initially expected and we believe congruent with the straight-forward non-oral benefit for route of delivery. Furthermore, we have detected a pattern within larger gastroenterology teams that the first physician adopting the use of Gimoti has led other physicians within the same practice to begin prescribing Gimoti as well. These market experiences follow the recently conducted market research announced in December 2021, which indicated, among other positive trends and benefits, that 92% of target gastroenterologists compared to 79% in a prior market research study, and 86-100% of non-target gastroenterologists and 89% of all respondents intend to prescribe Gimoti.

We expense all research and development expenses as they are incurred. Research and development expenses primarily include:

All of our research and development expenses to date have been incurred in connection with the development of Gimoti. ~~For the remainder~~Since FDA approval of ~~2017~~Gimoti in June 2020, research and development costs have decreased and shifted to commercialization and selling costs. In 2021, we ~~expect costs~~initiated planning, and are in discussion with FDA related to ~~our~~the design, for an FDA post-marketing commitment single dose PK clinical ~~development, including the analysis of data from the comparative exposure PK~~ trial ~~and pre-approval and pre-commercialization activities, including marketing and manufacturing~~ of Gimoti ~~and completion~~to characterize dose proportionality of a ~~planned NDA submission,~~lower dose strength of Gimoti to ~~continue. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming.~~accommodate patients that may require further dosage adjustments. We are unable to estimate with any certainty the costs we will incur inrelated to this trial, or the ~~continued~~regulatory review of such lower dosage of Gimoti, though such costs may be significant and will substantially increase research and development expenses once this trial is initiated. We may also incur additional costs to the extent we pursue additional clinical trials to expand the indication of Gimoti. Clinical development timelines, the probability of success and development costs can differ materially from expectations. ~~We may never succeed in achieving marketing approval for our product candidate.~~

The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:

~~General~~Selling, general and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation. Other selling, general and administrative expenses include professional fees for accounting, tax, patent costs, legal services, insurance, facility costs and costs associated with being a publicly-traded company, including fees associated with investor relations and directors and officers liability insurance premiums. We expect that selling, general and administrative expenses will increase in the future as we ~~expand our operating activities, prepare for the growth needs associated with commercialization and~~ continue to ~~incur additional costs associated~~progress with ~~being a publicly-traded company~~the commercialization of Gimoti and maintaining compliance with exchange listing and Securities and Exchange Commission requirements. These increases will likely include higher consulting costs, legal fees, accounting fees, directors’ and officers’ liability insurance premiums and fees associated with investor relations.

~~Other income (expense) consists~~we reimburse Eversana from the net profits attained from the sales of changes in the fair value of the warrant liability, which represents the change in the fair value of common stock warrants from reporting period to reporting period. The warrant liability relates to the warrants issued in the July 2016 Financing and August 2016 Financing, or collectively the 2016 Financings, and will be revalued each reporting period until the

~~liability is settled. We use the Black Scholes pricing model to value the related warrant liability. Other expense in 2016 also included interest expense incurred on our former outstanding debt.~~ Gimoti.

~~Our~~Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported ~~revenues and~~ expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.

~~The~~There have been no new or significant changes to our critical accounting policies and estimates ~~underlying the accompanying unaudited financial statements are those set forth~~discussed in ~~Part II, Item 7~~Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the ~~fiscal~~ year ended December 31, ~~2016, which was~~2021, filed with the SEC on March ~~15, 2017.~~

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board, regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, or IPO, (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. 8, 2022.

Comparison of Three Months Ended ~~September~~June 30, ~~2017~~2022 and ~~2016~~2021

The following table summarizes the results of our operations for the three months ended ~~September~~June 30, ~~2017~~2022 and ~~2016:~~2021:

Net Product Sales. Net product sales for the three months ended June 30, 2022 compared to the three months ended June 30, 2021 increased by approximately $225,000. The increase in sales was primarily driven by increased educational and promotional activities of the Eversana sales force during the three months ended June 30, 2022.

Research and Development Expenses. Research and development expenses for the three months ended ~~September~~June 30, ~~2017~~2022 compared to the three months ended ~~September~~June 30, ~~2016 increased~~2021 decreased by approximately ~~$1.4 million due primarily~~$4,000. During 2022 and 2021, we incurred expenses for ongoing stability testing of batches of Gimoti manufactured prior to ~~our comparative exposure PK trial being conducted~~receipt of FDA approval of the Gimoti NDA in June 2020.

Costs incurred during the ~~third quarter of 2017. Our Phase 3 clinical trial was completed during the second quarter of 2016~~three months ended June 30, 2022 included approximately $179,000 related to stability testing and ~~the analysis of the trial data occurred during the second half of 2016, so research and development costs were lower during the quarter ended September 30, 2016. Costs incurred in 2017 include~~ approximately ~~$1.8 million of clinical trial costs, approximately $601,000~~$13,000 for wages, taxes and employee insurance, including approximately ~~$201,000~~$3,800 of stock-based compensation ~~expense, and~~

expense. Costs incurred during the three months ended June 30, 2021 included approximately ~~$337,000~~$122,000 related to ~~costs associated with the preparation of an NDA. Costs incurred in 2016 include approximately $650,000 related~~

~~to the Phase 3 clinical trial for Gimoti, approximately $489,000~~manufacturing and $65,000 for wages, taxes and employee insurance, including approximately ~~$178,000~~$24,000 of stock-based compensation ~~expense, and approximately $193,000 related to costs associated with the preparation of an NDA.~~expense.

Selling, General and Administrative Expenses. ~~General~~Selling, general and administrative expenses for the three months ended ~~September~~June 30, ~~2017~~2022 compared to the three months ended ~~September~~June 30, ~~2016~~2021 increased by approximately ~~$154,000.~~$173,000. Costs incurred ~~in 2017~~during the three months ended June 30, 2022 primarily included approximately ~~$542,000~~$1.0 million for wages, taxes and employee insurance, including approximately ~~$275,000~~$363,000 of stock-based compensation expense, ~~and~~ approximately ~~$309,000~~$600,000 for legal, accounting, directors and officers liability insurance and other costs associated with being a public ~~company.~~company, approximately $640,000 for marketing, royalties and Eversana profit sharing, and approximately $47,000 for facility-related expenses. Costs incurred ~~in 2016~~during the three months ended June 30, 2021 primarily included approximately ~~$446,000~~$1.0 million for wages, taxes and employee insurance, including approximately ~~$274,000~~$376,000 of stock-based compensation expense, ~~and~~ approximately ~~$319,000~~$607,000 for legal, accounting, directors and officers liability insurance and other costs associated with being a public ~~company.~~

~~Other Expenses, net.~~ ~~Other expenses~~company, approximately $354,000 for the three months ended September 30, 2017 compared to the three months ended September 30, 2016 increased by approximately $685,000 due primarily to the increase of approximately $1.5 million in the fair value of the warrant liability, which resulted in a corresponding increase in other expense. Other expenses for the three months ended September 30, 2016 included approximately $534,000 of costs related to the 2016 Financings, an increase of approximately $199,000 in the fair value of the warrant liability,marketing, royalties and Eversana profit sharing, and approximately ~~$123,000 of interest expense incurred on our former outstanding debt with Square 1 Bank, or Square 1.~~$40,000 for facility-related expenses..

Comparison of ~~Nine~~Six Months Ended ~~September~~June 30, ~~2017~~2021 and ~~2016~~2020

The following table summarizes the results of our operations for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2022 and ~~2016:~~2021:

Nine Months Ended
September 30,

Increase/
Decrease

2017

2016

Research and development expenses

$
5,505,953

$
5,449,568

$
56,385

General and administrative expenses

$
3,065,595

$
2,770,500

$
295,095

Other expenses

$
3,349,521

$
1,001,120

$
2,348,401

	Six Months Ended June 30,				Increase/ (Decrease)
	2022		2021		Increase/ (Decrease)
Net product sales	$	880,175	$	327,056	$	553,119
Research and development expenses	$	233,194	$	473,054	$	(239,860	)
Selling, general and administrative expenses	$	4,720,251	$	4,480,443	$	239,808

Net Product Sales. Net product sales for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 increased by approximately $553,000. The increase in sales was primarily driven by increased educational and promotional activities of the Eversana sales force during the six months ended June 30, 2022.

Research and Development Expenses. Research and development expenses for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2022 compared to the ~~nine~~six months ended ~~September~~June 30, ~~2016~~2021 decreased by approximately $240,000. During 2022 and 2021, we incurred expenses for ongoing stability testing of batches of Gimoti manufactured prior to receipt of FDA approval of the Gimoti NDA in June 2020, as well as preparing for a post-marketing commitment to conduct a single dose PK clinical trial of Gimoti to characterize dose proportionality of a lower dose strength of Gimoti, including the manufacture of clinical trial material.

Costs incurred during the six months ended June 30, 2022 included approximately $214,000 for stability testing and $19,000 for wages, taxes and employee insurance, including approximately $5,600 of stock-based compensation expense. Cost incurred during the six months ended June 30, 2021, included approximately $233,000 for wages, taxes and employee insurance, including approximately $92,000 of stock-based compensation expense, and approximately $199,000 related to manufacturing.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 increased by approximately $56,000. During the first nine months of 2017, we were preparing for and conducting our comparative exposure PK trial, including product development activities and manufacturing Gimoti for such trial. In addition, we also were incurring costs associated with the preparation of an NDA.$240,000. Costs incurred ~~in 2017 include~~during the six months ended June 30, 2022 primarily included approximately $2.1 ~~million of clinical trial costs, approximately $1.9~~ million for wages, taxes and employee insurance, including approximately ~~$627,000~~$742,000 of stock-based compensation expense, approximately $958,000 related to manufacturing costs and approximately $561,000 related to costs associated with the preparation of the NDA. Costs incurred in 2016 include approximately $3.1 million related to the Phase 3 clinical trial for Gimoti, approximately $1.5 million for wages, taxes and employee insurance, including approximately $488,000 of stock-based compensation expense, and approximately $740,000 related to costs associated with the preparation of an NDA.

~~General and Administrative Expenses.~~ General and administrative expenses for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 increased by approximately $295,000. Costs incurred in 2017 primarily included approximately $1.6 million for wages, taxes and employee insurance, including approximately $778,000 of stock-based compensation expense and approximately $1.2$1.3 million for legal, accounting, directors and officers liability insurance and other costs associated with being a public ~~company.~~company, approximately $1.2 million for marketing, royalties and Eversana profit sharing, and approximately $90,000 for facility-related expenses. Costs incurred ~~in 2016~~during the six months ended June 30, 2021 primarily included approximately ~~$1.5~~$2.2 million for wages, taxes and employee insurance, including approximately ~~$811,000~~$869,000 of stock-based compensation expense, ~~and~~ approximately ~~$1.1~~$1.4 million for legal, accounting, directors and officers liability insurance and other costs associated with being a public ~~company.~~

~~Other Expenses.~~ ~~Other expenses~~company, approximately $567,000 for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 increased by approximately $2.3 million due primarily to the increase of approximately $3.4 million in the fair value of the warrant liability, which resulted in a corresponding increase in other expense. Other expenses for the nine months ended September 30, 2016 included approximately $534,000 of costs related to the 2016 Financings, an increase of approximately $199,000 in the fair value of the warrant liabilitymarketing, royalties and Eversana profit sharing, and approximately ~~$268,000 of interest expense incurred on our former outstanding debt with Square 1.~~$79,000 for facility-related expenses.

In November 2014, we entered into a sales agreement with MLV & Co., LLC, or the MLV Sales Agreement, which was subsequently acquired by FBR Capital Markets & Co., or FBR, pursuant to which we were able to sell from time to time, at our option, up to an aggregate of $6.6 million worth of shares of common stock through MLV, as sales agent. The sales of shares of our common stock made through this equity program were made in “at-the-market” offerings as defined in Rule 415 of the Securities Act. During the year ended December 31, 2015, we sold 1,048,507 shares of common stock at a weighted average price per share of $4.78 pursuant to the MLV Sales Agreement and received proceeds of approximately $4.9 million, net of commissions and fees. We did not sell any shares of common stock through the MLV Sales Agreement during 2016.

On April 15, 2016, we terminated the MLV Sales Agreement and entered into a new At Market Issuance Sales Agreement with FBR, or the FBR Sales Agreement, and filed a prospectus supplement, pursuant to which we may sell from time to time, at our option up to an aggregate of 649,074 shares of our common stock through FBR as the sales agent. Through December 31, 2016, we sold 56,000 shares of common stock and received net proceeds of approximately $296,000 under the FBR Sales Agreement. On March 10, 2017, we filed a prospectus supplement, which replaced the prospectus supplement filed on April 15, 2016, permitting us to sell up to an aggregate of $20.0 million of shares of our common stock through FBR as the sales agent. FBR was subsequently acquired by B. Riley Financial, Inc., or B. Riley. See Item 5 for additional details regarding FBR Sales Agreement.

~~Our current Form S-3~~ shelf registration statement ~~expires on November 25, 2017. Concurrently~~ with ~~filing this Quarterly Report~~the SEC on Form ~~10-Q, we are filing a new~~S-3. The shelf registration statement on Form S-3 which extends the effectiveness of the current shelf registration statement until the earlier of the date the SEC declares the new shelf registration statement effective or 6 months from the expiration date of the current shelf registration statement. The new shelf registration statement includesincluded a prospectus for the at-the-market offering to sell up to an aggregate of $16.0 million of shares of our common stock through B. Riley ~~(as successor by merger to FBR)~~FBR, Inc., or FBR, as a sales ~~agent. We remain subject~~agent, or FBR Sales Agreement. Effective January 6, 2021, we terminated the FBR Sales Agreement. As a result, there were no shares sold under the FBR Sales Agreement during 2021.

In December 2020, we filed a new shelf registration statement with the SEC on Form S-3, or the replacement shelf registration statement. The replacement shelf registration statement replaced the registration statement on Form S-3 we originally filed with the SEC in November 2017, which registration statement expired in December 2020. The replacement shelf registration was declared effective by the SEC on January 6, 2021. In December 2020, we also entered into the ATM Sales Agreement with FBR and H.C. Wainwright & Co., LLC, or the Sales Agents, pursuant to which we may sell from time to time, at our option, up to an aggregate of $30

million worth of shares of our common stock through the Sales Agents. The ATM Sales Agreement provides, among other things, that sales under the ATM Sales Agreement will be made pursuant to the ~~limitations~~registration statement, including the base prospectus filed as part of such registration statement. During 2021, we sold 18,091 shares of common stock at a weighted-average price per share of $17.64 pursuant to the ATM Sales Agreement and received proceeds of approximately $313,000, net of commissions and fees. During the six months ended June 30, 2022, we sold 621,697 shares of common stock at a weighted-average price per share of $11.97 pursuant to the ATM Sales Agreement and received proceeds of approximately $7.3 million, net of commissions and fees.

Under current SEC regulations, if at the time we file our Annual Report on Form 10-K our public float is less than $75 million, and for so long as our public float remains less than $75 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the baby shelf rules.

At the time we filed our Annual Report on Form 10-K on March 8, 2022, our public float was less than $75 million. As a result of our public float being below $75 million, we will be limited by the baby shelf rules ~~described below.~~until such time as our public float exceeds $75 million, which means we only have the capacity to sell shares up to one-third of our public float under shelf registration statements in any twelve-month period. If our public float decreases, the amount of securities we may sell under our Form S-3 shelf registration statement will also decrease. As of August 5, 2022, there was no capacity to issue additional shares of common stock pursuant to the ATM Sales Agreement. We will remain constrained by the baby shelf rules under our Form S-3 shelf registration statement until such time as our public float exceeds $75 million, at which time the number of securities we may sell under a Form S-3 registration statement will no longer be limited by the baby shelf rules.

Future sales under the ATM Sales Agreement will depend on a variety of factors including, but not limited to, market conditions, the trading price of our common stock and our capital needs. There can be no assurance that ~~FBR~~the Sales Agents will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate.

WeIn addition, we will not be able to make future sales of ~~our~~ common stock pursuant to the ~~FBR~~ATM Sales Agreement unless certain conditions are met, which include the accuracy of representations and warranties made to ~~FBR~~the Sales Agents under the ~~FBR~~ATM Sales Agreement. Furthermore, ~~FBR~~each of the Sales Agents is permitted to terminate the ~~FBR~~ATM Sales Agreement with respect to itself in its sole discretion upon ten days’ notice, or at any time in certain circumstances, including the occurrence of an event that would be reasonably likely to have a material adverse effect on our assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders’ equity or results of operations. We have no obligation to sell the ~~remaining~~ shares available for sale pursuant to the ~~FBR~~ATM Sales Agreement. ~~However, u~~nder current SEC regulations, at any time during which the aggregate market value of our common stock held by non-affiliates, or public float, is less than $75 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements, including sales under the FBR Sales Agreement, is limited to an aggregate of one-third of our public float. As of November 3, 2017, our public float was approximately $49.9 million, which means we may only sell shares up to one-third of our public float using shelf registration statements in any twelve-month period. We had no sales of common stock under the baby shelf rules in the twelve-month period ended November 3, 2017. If our public float decreases, the amount of securities we may sell under our Form S-3 shelf registration statements will also decrease.

In July 2016, we completed an at-the-market offering of 1,804,512 shares of common stock at a purchase price of $2.49375 per share, or the July 2016 Financing. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received an unregistered warrant to purchase three-quarters of a share of our common stock, for a total of 1,353,384 shares, or the July Warrants. The July Warrants have an exercise price of $2.41 per share, are immediately exercisable and will expire on January 25, 2022. The aggregate gross proceeds from the sale of the common stock and warrants were $4.5 million, and the net proceeds after deduction of commissions and fees were approximately $4.0 million.

In connection with the ~~July 2016 Financing,~~Eversana Agreement, we ~~issued~~entered into the Eversana Credit Facility, pursuant to ~~our placement agent, Rodman & Renshaw,~~which Eversana agreed to provide a ~~unit~~revolving credit facility of ~~H.C. Wainwright & Co. LLC, or Wainwright, and~~up to $5 million to us upon FDA approval of the Gimoti NDA, as well as certain other customary conditions. The Eversana Credit Facility terminates on June 19, 2025, unless terminated earlier pursuant to its ~~designees unregistered warrants to purchase an aggregate of 90,226 share~~terms. The Eversana Credit Facility is secured by all of our ~~common stock, or~~personal property other than our intellectual property. Under the ~~July Wainwright Warrants. The July Wainwright Warrants have substantially~~terms of the ~~same terms as~~Eversana Credit Facility, we cannot grant an interest in our intellectual property to any other person. Each loan under the ~~July Warrants, except that the July Wainwright Warrants~~Eversana Credit Facility will ~~expire on July 21, 2021 and have~~bear interest at an ~~exercise price~~annual rate equal to ~~$3.1172 per share~~10.0%, with such interest due at the end of ~~common stock.~~

the loan term. In ~~August 2016,~~2020 we completed an at-the-market offering of 3,244,120 shares of common stock at a purchase price of $3.0825 per share, the August 2016 Financing. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received from an unregistered warrant to purchase one half of a share of our common stock, for a total of 1,622,060 shares, or August Warrants. The August Warrants have an exercise price of $3.03 per share, are immediately exercisable and will

~~expire on February 3, 2022. The aggregate gross proceeds~~borrowed $5 million from the ~~sale of the common stock and warrants were $10.0 million, and the net proceeds after deduction of commissions and fees were approximately $9.2 million.~~Eversana Credit Facility.

In connection with the August 2016 Financing, we issued to our placement agent, Wainwright, and its designees unregistered warrants to purchase an aggregate of 162,206 shares of our common stock, or the August Wainwright Warrants. The August Wainwright Warrants have substantially the same terms as the August Warrants, except that the August Wainwright Warrants will expire on July 29,January 2021, ~~and have an exercise price equal to $3.853125 per share of common stock.~~

On February 16, 2017, an institutional investor from our financing which closed in July 2016 converted its warrant to purchase 526,315 shares of our common stock by a “cashless” exercise and received 211,860 shares of the our common stock. The warrant had an exercise price of $2.41 per share. The shares were issued, and the warrants were sold, in reliance upon the registration exemption set forth in Section 4(a)(2) of the Securities Act of 1933, as amended. The value of the exercised warrants were adjusted to their fair value immediately prior to the exercise and approximately $1.4 million was reclassified from warrant liability to Additional Paid-in Capital. Subsequent to this transaction, warrants to purchase 2,449,129 shares of our common stock remain classified as a liability.

~~In February and March 2017,~~ we completed the sale of ~~2,775,861~~479,166 shares of our common stock in an underwritten public offering led by Laidlaw & Company (UK) Ltd. The price to the public in this offering was ~~$2.90~~$30.00 per share resulting in gross proceeds to us of approximately ~~$8.0~~$14.4 million. After deducting underwriting discounts and commissions, and ~~estimated~~ offering expenses ~~payable~~paid by us, the net proceeds to us raised from this offering ~~was~~were approximately ~~$7.3~~$13.1 million.

On August 4, 2016, we repaid in full the entire $4.5 million of outstanding principal and interest under the Loan and Security Agreement, or the Loan Agreement, between us and Square 1. In connection with such repayment, the Loan Agreement was terminated, and all security, liens or other encumbrances on assets of ours were released.

We incurred $82,685 of loan origination costs related to this credit facility. The remaining unamortized costs of approximately $38,000 were charged to interest expense upon the payment of the loan in August 2016.

In connection with the funding of the term loan, we issued to Square 1 a warrant to purchase 22,881 shares of our common stock at an exercise price of $5.90 per share, the closing price of our common stock on the day of funding of the credit facility. During July 2016, Square 1 converted its warrant by a “cashless” conversion and received 9,887 shares of our common stock. The value determined for the warrant at the time of the grant of $108,122 was recorded as a debt discount, as well as to stockholders’ equity. The remaining unamortized debt discount associated with the warrant of approximately $59,000 was charged to interest expense upon the payment of the loan in August 2016.

~~Our independent registered public accounting firm included an explanatory paragraph in their report on our financial statements as of and for the year ended December 31, 2016 with respect to~~Management concluded that there is substantial doubt about our ability to continue as a going concern. This doubt about our ability to continue as a going concern ~~opinion~~for at least twelve months from the date of issuance of the financial statements could materially limit our ability to raise additional funds through the issuance of new debt or equity securities or otherwise. Future reports by our independent registered accounting firm on our financial statements may also include an explanatory paragraph with respect to our ability to continue as a going concern. We have incurred significant losses since our inception and have never been profitable, and it is possible we will never achieve profitability. We ~~have devoted~~believe, based on our ~~resources to developing~~current operating plan, that our cash and cash equivalents as of June 30, 2022 of approximately $13.5 million, as well as future cash flows from net sales of Gimoti, ~~but it cannot~~will be ~~marketed until regulatory approvals have been obtained. Based upon our currently expected level of operating expenditures, we expect to be able~~sufficient to fund our operations ~~through at least June 2018.~~into the second quarter of 2023. This period could be shortened if there are any significant increases in planned spending other than anticipated. We anticipate we will be required to raise additional funds in order to continue as a going concern. Because our business is entirely dependent on the success of Gimoti, if we are unable to secure additional financing or identify and execute on other development or strategic alternatives for Gimoti or our ~~Gimoti development program, including the analysis~~company, we will be required to curtail all of ~~data from~~ our ~~completed comparative exposure PK trial, pre-approval~~activities and ~~pre-commercialization~~may be required to liquidate, dissolve or otherwise wind down our operations. Any of these events could result in a complete loss of your investment in our securities.

These estimates of cash runway could be shortened if there are any significant increases in planned spending on commercialization activities, including for marketing and manufacturing of Gimoti, ~~completion of a planned NDA submission, including whether or not FDA grants~~and our ~~request to waive the user fees that would otherwise become due upon our filing of an NDA with FDA, and our~~selling, general and administrative costs to support operations. There is no assurance that other financing will be available when needed to allow us to continue as a going concern. The perception that

we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations.

On December 29, 2021, we received a letter from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market.

In accordance with Nasdaq listing rules, we were provided an initial period of 180 calendar days, or until June 27, 2022, to regain compliance. The letter states that Nasdaq will provide written notification that we have achieved compliance with its rules if at any time before June 27, 2022, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq letter had no immediate effect on the listing or trading of our common stock and the common stock continued to trade on The Nasdaq Capital Market.

On April 27, 2022, our stockholders granted the board of directors the authority to effect a reverse stock split of our outstanding common stock. On May 23, 2022, we effected a 1-for-12 reverse stock split of the shares of our common stock, or the Reverse Stock Split. The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of our issued and outstanding common stock, warrants to purchase common stock, and options to purchase common stock have been adjusted to reflect the Reverse Stock Split.

On June 7, 2022, we received notice from Nasdaq stating that the closing price of our common stock has been $1.00 per share or greater for the prior ten consecutive business days and that we had regained compliance with the minimum $1.00 per share requirement.

We expect to continue to incur expenses ~~and increase operating losses for at least the next several years. In the near-term, we anticipate incurring costs~~ as we:

Although our current cash and cash equivalents are expected to be sufficient to fund our operations through at least June 2018, it may not be sufficient to complete any additional development requirements requested by FDA. Accordingly, we will continue to require substantial additional capital beyond our current cash and cash equivalents to continue our clinical and regulatory development and potential commercialization activities. The amount and timing of our future funding requirements will depend on many factors further described below, including the analysis of the full results of the comparative exposure PK trial, the costs associated with completing and submitting the Gimoti NDA and the extent of any additional clinical development required by FDA. We anticipate that we will seek to fund our operations through public or private equity or debt financings or other sources, such as potential collaboration arrangements. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategies.

The following table summarizes our cash flows for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2022 and ~~2016:~~2021:

Operating Activities. The primary use of our cash has been to fund our clinical research, prepare our NDA, manufacture Gimoti, prepare for and begin commercial sales of Gimoti, and other general operations. The cash used in operating activities ~~decreased in 2017 as we have been preparing~~during the six months ended June 30, 2022 and 2021 was primarily related to commercialization activities for Gimoti and ~~conducting our comparative exposure PK clinical trial and the manufacturing of Gimoti for such trial.~~other general operational activities. We expect that cash used in operating activities will increase ~~throughout~~during the remainder of ~~2017 as those projects, as well as~~2022 due to commercialization activities, including manufacturing of Gimoti, and the ~~preparation~~planned post-marketing commitment to conduct a single dose PK clinical trial of ~~the NDA and pre-approval and pre-commercialization activities, continue.~~Gimoti to characterize dose proportionality of a lower dose strength of Gimoti.

Financing Activities. During the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2022, we received net proceeds of approximately $7.3 million from the sale of 2,775,861 shares of common stock in an underwritten public offering. In addition, we received proceeds of approximately $135,000 from the sale of 75,529 shares of common stock through our employee stock purchase plan, or ESPP. During the nine months ended September 30, 2016, we received net proceeds of approximately $13.2 million through the 2016 Financings from the sale of 5,048,632 shares of common stock and 2,975,444 warrants to purchase our common stock. In addition, we received net proceeds of approximately $358,000 from the sale of 56,000621,697 shares of common stock pursuant to the ~~FBR~~ATM Sales ~~Agreement and~~Agreement. During the six months ended June 30, 2021 we received net proceeds of approximately $13.1 million from the sale of ~~34,067~~479,166 shares of common stock ~~through our ESPP.~~

~~We believe that our existing cash~~pursuant to an underwritten public offering and ~~cash equivalents as~~approximately $45,000 from the exercise of ~~September 30, 2017, together with interest thereon, will be sufficient~~stock options to ~~meet our anticipated cash requirements through at least June 2018. However, our forecast~~purchase 5,618 shares of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. common stock.

The amount and timing of our future funding requirements will depend on many factors, including but not limited to:

Through ~~September~~June 30, ~~2017,~~2022, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.

~~In December 2016, we entered into an operating lease~~There were no material changes outside the ordinary course of our business during the six months ended June 30, 2022 to the information regarding our contractual obligations that was disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for ~~office space in Solana Beach, California. The lease commenced on January 1, 2017 with an expiration date of~~the year ended December 31, ~~2018. We also pay pass through costs and utility costs, which are expensed as incurred.~~2021, filed with the SEC on March 8, 2022.

As of September 30, 2017, there have been no material changes in our market risk from that described in “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Quantitative and Qualitative Disclosures about Market Risk” in our Annual Report on Form 10-K fora smaller reporting company, we are not required to provide the ~~fiscal year ended December 31, 2016.~~information required by this Item.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the ~~Securities and Exchange Commission’s~~SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Business Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by ~~Securities and Exchange Commission~~SEC Rule 13a-15(b), as of June 30, 2022 we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Business Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Business Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of ~~September~~June 30, ~~2017.~~2022.

There ~~have been~~were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during ~~our most recent fiscal~~the quarter ended June 30, 2022 that ~~have~~ materially ~~affected,~~affect, or are reasonably likely to materially affect, our internal control over financial reporting.

WeOn February 25, 2022, we received a letter notifying us that Teva submitted to FDA an abbreviated new drug application, or ANDA, for a generic version of Gimoti (metoclopramide hydrochloride) nasal spray eq. 15 mg base/spray that contains Paragraph IV certifications with respect to two of our patents covering Gimoti, U.S. Patent Nos. 8,334,281, expiration date May 16, 2030; and 11,02,0361, expiration date December 22, 2029. These patents are ~~currently~~listed in FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for Gimoti. The certifications allege these patents are invalid or will not ~~a party to any~~be infringed by the manufacture, use or sale of Teva’s metoclopramide hydrochloride nasal spray eq. 15 mg base/spray. In

April 2022, we initiated litigation in the United States District Court for the District of New Jersey alleging that Teva infringes the patents covering Gimoti. Teva has denied all material ~~legal proceedings.~~allegations and asserted counterclaims of non-infringement and invalidity.

There have been no material changes to the risk factors included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2016,~~2021, filed with the SEC on March 8, 2022 other than ~~those set forth below,~~as follows:

We may require substantial additional funding and may be unable to raise capital when needed, which ~~should be read in conjunction with the risk factors disclosed therein.~~would force us to liquidate, dissolve or otherwise wind down our operations.

Our ~~business is entirely dependent~~operations have consumed substantial amounts of cash since inception. We believe, based on ~~the success~~our current operating plan, that our cash and cash equivalents as of June 30, 2022 of approximately $13.5 million, as well as cash flows from net sales of Gimoti, ~~which failed~~will be sufficient to ~~achieve~~fund our operations into the ~~primary endpoint~~second quarter of ~~symptom improvement~~2023. This period could be shortened if there are any significant increases in planned spending other than anticipated. We anticipate that we will be required to raise additional funds through debt, equity or other forms of financing, such as potential collaboration arrangements, to fund future operations and continue as a Phase 3 clinical trial in female patients with symptoms associated with diabetic gastroparesis. While we are continuing to pursue regulatory approval based on the results of our completed comparative exposure PK trial, we cannotgoing concern. There can be ~~certain~~no assurance that we will be able to ~~obtain regulatory approval for,~~raise additional funds on acceptable terms, or ~~successfully commercialize, Gimoti.~~

To date, we have devoted all of our research, development and clinical efforts and financial resources toward the development of Gimoti, our patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women. Gimoti is our only product candidate. In July 2016, we announced topline results from our Phase 3 clinical trial that evaluated the efficacy and safety of Gimoti in women with symptoms associated with diabetic gastroparesis. In this study, Gimoti did not achieve its primary endpoint of symptom improvement in the Intent-to-Treat (ITT) group at Week 4.

In December 2016, we announced the completion of a second pre-NDA meeting with FDA, in which FDA agreed that a comparative exposure PK trial was acceptable as a basis for submission of a Gimoti NDA. The comparative exposure PK trial will serve as a portion of the full 505(b)(2) data package to include prior efficacy and safety data developed by us and the FDA’s prior findings of safety and efficacy for the Listed Drug, Reglan Tablets. On October 23, 2017, we announced positive topline results from the comparative exposure PK trial and plan to submit the Gimoti NDA during the first quarter of 2018. Although we believe the PK trial establishes bioequivalence, FDA may later determine to require the conduct of additional efficacy or safety trials, and we may be unable to submit an NDA on this timeframe, or potentially at all.

Because our business is entirely dependent on the success of Gimoti, if we are unable to secure additional financing, successfully ~~complete development of~~commercialize Gimoti or identify and ~~receive regulatory approval of this product candidate,~~execute on other commercialization or strategic alternatives for Gimoti or our company, we will be required to curtail all of our activities and may be required to liquidate, dissolve or otherwise wind down our operations. Any of these events could result in ~~the~~a complete loss of anyour investment in our securities.

~~In addition to the above factors, the future regulatory and commercial success of Gimoti is subject to a number of additional risks, including the following:~~

~~We will require substantial additional funding and may be unable to raise capital when needed, which would force us to liquidate, dissolve or otherwise wind down our operations.~~

Our operations have consumed substantial amounts of cash since inception. We believe, based on our current operating plan, that our existing cash and cash equivalents will be sufficient to fund our operations through at least June 2018, although there can be no assurance in that regard. We will be required to raise additional funds in order to continue as a going concern beyond that time.

Our estimates of the amount of cash necessary to fund our activities may prove to be wrong and we could spend our available financial resources much faster than we currently expect. Our future funding requirements will depend on many factors, including, but not limited to:

Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. Furthermore, the issuance of additional shares or other securities by us, or the possibility of such issuance, may cause the market price of our shares to decline and dilute the holdings of our existing stockholders. If we raise additional funds by incurring debt, the terms of the debt may involve significant cash payment obligations, as well as covenants and specific financial ratios that may restrict our ability to operate our business. We cannot provide any assurance that our existing capital resources will be sufficient to enable us to identify or execute a viable plan for continued clinical development of Gimoti or to otherwise survive as a going concern.

~~Topline data may~~ If adequate funds are not ~~accurately reflect the complete results of a particular study or trial~~.

~~We may publicly disclose topline or interim data from time~~available to time, which is based on a preliminary analysis of then-available data such as the topline results we reported from the comparative exposure PK trial, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, andus, we may not ~~have received~~be able to make scheduled debt payments on a timely basis, or ~~had the opportunity to fully~~at all, and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially

~~different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.~~

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. For example, while we believe that the AUC measurement is the most clinically relevant PK parameter for this comparative exposure PK trial based on discussions with FDA at previous pre-NDA meetings, the FDA may change their view regarding C_max falling below the bioequivalence range of Reglan Tablets as it relates to selecting our dose and more generally in the FDA’s review of our planned NDA submission. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be ~~harmed, which could harm~~required to delay, limit, reduce or cease our business, operating results, prospects or financial condition. Further, although we have reported positive topline data for the PK trial, the FDA may still require the conduct of additional efficacy or safety trials prior to our planned NDA submission.operations.

On November 14, 2017, substantially concurrently with this Current Report on Form 10-Q, we will file a shelf registration statement on Form S-3, or the replacement shelf registration statement, with the SEC, which has not yet been declared effective. The replacement registration statement is replacing the registration statement on Form S-3 we originally filed with the SEC on November 13, 2014, which registration statement is set to expire on November 25, 2017. On November 14, 2017, we entered into an amendment, or the Amendment, to the FBR Sales Agreement, pursuant to which sales agreement we may sell from time to time, at our option, shares of common stock through FBR, as sales agent. The Amendment provides, among other things, that sales under the FBR Sales Agreement will be made pursuant to the replacement registration statement, including the base prospectus filed as part of such registration statement, as of and effective upon the SEC declaring such replacement registration statement effective. Sales under the FBR Sales Agreement will continue to be made, if any, pursuant to the original registration statement until the earlier of the effectiveness of the replacement registration statement or 180 days following the expiration of the original registration statement. The Amendment will be effective concurrently with the effectiveness of the replacement shelf registration statement. The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as Exhibit 1.2 to the replacement shelf registration statement and is incorporated herein by reference. Please refer to the description of the FBR Sales Agreement in the Liquidity and Capital Resources section contained in Item 2 above. Additional information with respect to the FBR Sales Agreement is available in the current report on Form 8-K filed by us with the SEC on April 15, 2016, and is hereby incorporated by reference. The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the FBR Sales Agreement, a copy of which is filed as Exhibit 1.1 to the current report on Form 8-K filed with the SEC on April 15, 2016.None.

~~A list of exhibits is set forth below and is incorporated herein by reference.~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Delaware		20-8447886
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

420 Stevens Avenue, Suite 370, Solana Beach, CA		92075
(Address of principal executive offices)		(Zip Code)


Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	EVOK	The Nasdaq Capital Market

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Common stock subject to repurchase		45,000		45,000		45,000		45,000
Warrants to purchase common stock		2,797,561		3,323,876		2,771,685		3,323,876
Common stock options		2,131,624		1,275,624		2,131,624		1,275,624
Employee stock purchase plan		7,064		10,938		7,064		10,938
Total excluded securities		4,981,249		4,655,438		4,955,373		4,655,438

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Warrants to purchase common stock		—		153,490		—		153,490
Common stock options		491,851		460,642		491,851		460,642
Total excluded securities		491,851		614,132		491,851		614,132

PART I. FINANCIAL INFORMATION		1
Item 1. Financial Statements		1
Condensed Balance Sheets as of ~~September~~June 30, ~~2017~~2022 (Unaudited) and December 31, ~~2016~~2021		1
Condensed Statements of Operations for the three and ~~nine~~six months ended ~~September, 2017~~June 30, 2022 and ~~2016~~2021 (Unaudited)		2
Condensed Statements of Stockholders’ Equity for the three and six months ended June 30, 2022 and 2021 (Unaudited)		3
Condensed Statements of Cash Flows for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2022 and ~~2016~~2021 (Unaudited)	3	4
Notes to Condensed Financial Statements (Unaudited)	4	5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	12	13
Item 3. Quantitative and Qualitative Disclosures about Market Risk	20	21
Item 4. Controls and Procedures		21
PART II. OTHER INFORMATION		21
Item 1. Legal Proceedings		21
Item 1A. Risk Factors		22
~~Item 1. Legal Proceedings~~	22
~~Item 1A. Risk Factors~~	22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	24	22
Item 3. Defaults Upon Senior Securities	24	22
Item 4. Mine Safety Disclosures		23
Item 5. Other Information		23
Item 6. Exhibits		24
~~Item 5. Other Information~~	24
~~Item 6. Exhibits~~SIGNATURES		25
~~SIGNATURES~~	26

	Three and Nine Months Ended September 30,				Three Months Ended June 30,		Six Months Ended June 30,
	2017		2016		2022	2021	2022	2021
Common Stock Options
Risk free interest rate	1.93% - 2.16%		1.25% - 1.58%		2.82% - 3.55%	0.91% - 1.08%	1.67% - 3.55%	0.57% - 1.08%
Expected option term	5.5 - 6.0 years		5.3 - 6.0 years		5.5 - 6.0 years	5.5 - 6.0 years	5.5 - 6.0 years	5.5 - 6.0 years
Expected volatility of common stock	94.05% - 98.25%		74.44% - 75.91%		97.04% - 113.23%	105.93%-107.53%	97.04% - 113.23%	103.45%-107.53%
Expected dividend yield		0.0%		0.0%	0.0%	0.0%	0.0%	0.0%

	Three and Six Months Ended June 30, 2022		Three and Six Months Ended June 30, 2021
Employee Stock Purchase Plan
Risk free interest rate		—	0.13%
Expected term		—	0.5 years
Expected volatility of common stock		—	111.98%
Expected dividend yield		—	0.0%

	September 30, 2017		December 31, 2016
Risk-free interest rate		1.77%		1.93%
Expected volatility		100.41%		94.19%
Expected term	4.33 years		5.08 years
Expected dividend yield		0.0%		0.0%

	Level 1		Level 2		Level 3		Total
Warrant liability
Balance at September 30, 2017	$	-	$	-	$	6,050,901	$	6,050,901

Balance at December 31, 2016	$	-	$	-	$	4,095,019	$	4,095,019

	Warrant Liability
Balance at December 31, 2016	$	4,095,019
Issuance of warrants	—
Change in fair value upon re-measurement		3,354,973
Reclassification to Additional Paid-in Capital due to warrant exercise		(1,399,091	)
Balance at September 30, 2017	$	6,050,901

	Nine Months Ended September 30,				Increase/ Decrease
	2017		2016		Increase/ Decrease
Research and development expenses	$	5,505,953	$	5,449,568	$	56,385
General and administrative expenses	$	3,065,595	$	2,770,500	$	295,095
Other expenses	$	3,349,521	$	1,001,120	$	2,348,401

Exhibit Number		Description of Exhibit

3.1 ~~(1)~~		Amended and Restated Certificate of Incorporation of the Company,as amended

3.2 (1)		Amended and Restated Bylaws of the Company

4.1 (2)		Form of the Company’s Common Stock Certificate

~~4.2 (3)~~	~~Investor Rights Agreement dated as of June 1, 2007~~

~~4.3 (3)~~	~~Warrant dated June 1, 2012 issued by the Company to Silicon Valley Bank~~

~~4.4 (2)~~	Form of Warrant Agreement dated September 30, 2013 issued by the Company to the representative of the underwriters and certain of its affiliates in connection with the closing of the Company’s initial public offering

~~4.5 (4)~~	~~Form of Warrant issued by the Company to certain investors under the Securities Purchase Agreement between the Company and such investors dated July 20, 2016~~

~~4.6 (5)~~	~~Form of Warrant issued by the Company to certain investors under the Securities Purchase Agreement between the Company and such investors dated July 29, 2016~~

31.1*		Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934

31.2*		Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934

32.1*		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document

101.SCH		Inline XBRL Taxonomy Extension Schema ~~Document~~

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase ~~Document~~

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase ~~Document~~

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase ~~Document~~

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase ~~Document~~

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

	Evoke Pharma, Inc.

Date: ~~November 14, 2017~~August 10, 2022	By:	/s/ David A. Gonyer
		David A. Gonyer President and Chief Executive Officer (Principal Executive Officer)

Date: ~~November 14, 2017~~August 10, 2022	By:	/s/ Matthew J. D’Onofrio
		Matthew J. D’Onofrio Executive Vice President, Chief Business Officer, Treasurer and Secretary (Principal Financial and Accounting Officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ ~~(Do not check if a smaller reporting company)~~☒

Smaller reporting company

Emerging growth company ☒☐